CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β-HYDROXYSTEROID

DEHYDROGENASE 1

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/903,473, filed February 26, 2007, the entire teachings of which are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to inhibitors of 11 β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), pharmaceutical compositions thereof and methods of using the same.

BACKGROUND OF THE INVENTION

Glucocorticoids, such as Cortisol (hydrocortisone), are steroid hormones that regulate fat metabolism, function and distribution, and play a role in carbohydrate, protein and fat metabolism. Glucocorticoids are also known to have physiological effects on development, neurobiology, inflammation, blood pressure, metabolism and programmed cell death. Cortisol and other corticosteroids bind both the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR), which are members of the nuclear hormone receptor superfamily and have been shown to mediate Cortisol function in vivo. These receptors directly modulate transcription via DNA-binding zinc finger domains and transcriptional activation domains.

Until recently, the major determinants of glucocorticoid action were attributed to three primary factors: (1) circulating levels of glucocorticoid (driven primarily by the hypothalamic-pituitary-adrenal (HPA) axis); (2) protein binding of glucocorticoids in circulation; and (3) intracellular receptor density inside target tissues. Recently, a fourth determinant of glucocorticoid function has been identified: tissue-specific pre-receptor metabolism by glucocorticoid-activating and -inactivating enzymes. These 11 β- hydroxysteroid dehydrogenase (11β-HSD) pre-receptor control enzymes modulate activation of GR and MR by regulation of glucocorticoid hormones. To date, two distinct isozymes of 11-beta-HSD have been cloned and characterized: 11β-HSD1 (also known as 11-beta-HSD type 1 , 11 betaHSD1 , HSD11B1 , HDL, and HSD11 L) and 11 β-HSD2. 1 1 β- HSD1 is a bi-directional oxidoreductase that regenerates active Cortisol from inactive 11-

keto forms, whereas 11β-HSD2 is a unidirectional dehydrogenase that inactivates biologically active Cortisol by converting it into cortisone.

The two isoforms are expressed in a distinct tissue-specific fashion, consistent with the differences in their physiological roles. 11 β-HSD1 is widely distributed in rat and human tissues; expression of the enzyme and corresponding mRNA have been detected in human liver, adipose tissue, lung, testis, bone and ciliary epithelium. In adipose tissue, increased Cortisol concentrations stimulate adipocyte differentiation and may play a role in promoting visceral obesity. In the eye, 11β-HSD1 may regulate intraocular pressure and may contribute to glaucoma; some data suggest that inhibition of 11β-HSD1 may cause a drop in intraocular pressure in patients with intraocular hypertension (Kotelevstev et al. (1997), Proc. Natl. Acad. Sci. USA 94(26): 14924-9). Although 11 β-HSD1 catalyzes both 11-beta- dehydrogenation and the reverse 11-oxoreduction reaction, 11β-HSD1 acts predominantly as a NADPH-dependent oxoreductase in intact cells and tissues, catalyzing the formation of active Cortisol from inert cortisone (Low et al. (1994) J. MoI. Endocrin. 13: 167-174). In contradistinction, 11 β-HSD2 expression is found mainly in mineralocorticoid target tissues such as kidney (cortex and medulla), placenta, sigmoid and rectal colon, salivary gland and colonic epithelial cell lines. 11β-HSD2 acts as an NAD-dependent dehydrogenase catalyzing the inactivation of Cortisol to cortisone (Albiston et al. (1994) MoI. Cell. Endocrin. 105: R11-R17), and has been shown to protect the MR from glucocorticoid excess (e.g., high levels of receptor-active Cortisol) (Blum, et al. (2003) Prog. Nucl. Acid Res. MoI. Biol. 75:173-216).

Mutations in either the 11β-HSD1 or the 11β-HSD2 genes result in human pathology. For example, individuals with mutations in 11 β-HSD2 are deficient in this cortisol-inactivation activity and, as a result, present with a syndrome of apparent mineralocorticoid excess (also referred to as ^' SAME') characterized by hypertension, hypokalemia, and sodium retention (Edwards et al. (1988) Lancet 2: 986-989; Wilson et al. (1998) Proc. Natl. Acad. Sci. 95: 10200-10205). Similarly, mutations in 11 β-HSD1 and in the gene encoding a co-localized NADPH-generating enzyme, hexose 6-phosphate dehydrogenase (H6PD), can result in cortisone reductase deficiency (CRD); these individuals present with ACTH-mediated androgen excess (hirsutism, menstrual irregularity, hyperandrogenism), a pheπotype resembling polycystic ovary syndrome (PCOS) (Draper et al. (2003) Nat. Genet. 34: 434- 439).

Notably, disruption of homeostasis in the HPA axis by either deficient or excess secretion or action results in Cushing's syndrome or Addison's disease, respectively (Miller and Chrousos (2001) Endocrinology and Metabolism, eds Felig and Frohman (McGraw-Hill, New York), 4 ^th Ed 387-524) Patients with Cushing's syndrome or receiving glucocorticoid therapy develop reversible visceral fat obesity The phenotype of Cushing's syndrome patients closely resembles that of Reaven's metabolic syndrome (also known as Syndrome X or insulin resistance syndrome), the symptoms of which include visceral obesity, glucose intolerance, insulin resistance, hypertension, type 2 diabetes and hyperlipemia (Reaven (1993) Ann Rev Med 44 121-131) Although the role of glucocorticoids in human obesity is not fully characterized, there is mounting evidence that 11β-HSD1 activity plays an important role in obesity and metabolic syndrome (Bujalska et al (1997) Lancet 349 1210- 1213), (Livingstone et al (2000) Endocrinology 131 560-563, Rask et al (2001) J CIm Endocrinol Metab 86 1418-1421 , Lindsay et al (2003) J CIm Endocrinol Metab 88 2738-2744, Wake et al (2003) J CIm Endocrinol Metab 88 3983-3988)

Data from studies in mouse transgenic models supports the hypothesis that adipocyte 11β-HSD1 activity plays a central role in visceral obesity and metabolic syndrome (Alberts et al (2002) Diabetologia 45(11) 1526-32) Over-expression in adipose tissue of 11β-HSD1 under the control of the aP2 promoter in transgenic mice produced a phenotype remarkably similar to human metabolic syndrome (Masuzaki et al (2001) Science 294

2166-2170, Masuzaki et al (2003) J Clinical Invest 112 83-90) Moreover, the increased activity of 11β-HSD1 in these mice is very similar to that observed in human obesity (Rask et al (2001) J CIm Endocrinol Metab 86 1418-1421) In addition, data from studies with 11 β-HSD1 -deficient mice produced by homologous recombination demonstrate that the loss of 11β-HSD1 leads to an increase in insulin sensitivity and glucose tolerance due to a tissue-specific deficiency in active glucocorticoid levels (Kotelevstev et al (1997) Proc Natl Acad Sci 94 14924-14929, Morton et al (2001) J Biol Chem 276 41293-41300, Morton et al (2004) Diabetes 53 931-938)

The published data supports the hypothesis that increased expression of 11 β-HSD1 contributes to increased local conversion of cortisone to Cortisol in adipose tissue and hence that 11β-HSD1 plays a role in the pathogenesis of central obesity and the appearance of the metabolic syndrome in humans (Engeli, et al , (2004) Obes Res 12 9-17) Therefore, 11 β- HSD1 is a promising pharmaceutical target for the treatment of the metabolic syndrome (Masuzaki, et al , (2003) Curr Drug Targets Immune Endocr Metabol Disord 3 255-62)

Furthermore, inhibition of 11β-HSD1 activity may prove beneficial in treating numerous glucocorticoid-related disorders. For example, 11β-HSD1 inhibitors could be effective in combating obesity and/or aspects of the metabolic syndrome cluster, including glucose intolerance, insulin resistance, hyperglycemia, hypertension, and/or hyperlipidemia (Kotelevstev et al. (1997) Proc. Natl. Acad. Sci. 94: 14924-14929; Morton et al. (2001) J. Biol. Chem. 276: 41293-41300; Morton et al. (2004) Diabetes 53: 931-938). In addition, inhibition of 11β-HSD1 activity may have beneficial effects on the pancreas, including the enhancement of glucose-stimulated insulin release (Billaudel and Sutter (1979) Horm. Metab. Res. 11 : 555-560; Ogawa et al. (1992) J. Clin. Invest. 90: 497-504; Davani et al. (2000) J. Biol. Chem. 275: 34841-34844). Furthermore, given that inter-individual differences in general cognitive function have been linked to variability in the long-term exposure to glucocorticoids (Lupien et al. (1998) Nat. Neurosci. 1: 69-73) and dysregulation of the HPA axis resulting in chronic exposure to glucocorticoid excess in certain brain subregions has been theorized to contribute to the decline of cognitive function (McEwen and Sapolsky (1995) Curr. Opin. Neurobiol. 5: 205-216), one might predict that inhibition of 11β-HSD1 could reduce exposure to glucocorticoids in the brain and thereby protect against deleterious glucocorticoid effects on neuronal function, including cognitive impairment, dementia, and/or depression.

There is also evidence that glucocorticoids and 11 β-HSD1 play a role in regulation of in intra-ocular pressure (lOP) (Stokes et al. (2000) Invest. Ophthalmol. Vis. Sci. 41 : 1629- 1683; Rauz et al. (2001) Invest. Ophthalmol. Vis. Sci. 42: 2037-2042); if left untreated, elevated IOP can lead to partial visual field loss and eventually blindness. Thus, inhibition of 11β-HSD1 in the eye could reduce local glucocorticoid concentrations and IOP, and 11 β- HSD1 hence could potentially be used to treat or prevent glaucoma and other visual disorders.

Transgenic aP2-1 1βHSD1 mice exhibit high arterial blood pressure and have increased sensitivity to dietary salt. Moreover, plasma angiotensinogen levels are elevated in the transgenic mice, as are angiotensin Il and aldosterone; and treatment of the mice with an angiotensin Il antagonist alleviates the hypertension (Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90). This suggests that hypertension may be caused or exacerbated by 11β-HSD1 activity. Thus, 11β-HSD1 inhibitors may be useful for treatment of hypertension and hypertension-related cardiovascular disorders.

Glucocorticoids can have adverse effects on skeletal tissues; and prolonged exposure to even moderate glucocorticoid doses can result in osteoporosis (Cannalis (1996) J. Clin. Endocrinol. Metab. 81 : 3441-3447). In addition, 11β-HSD1 has been shown to be present in cultures of human primary osteoblasts as well as cells from adult bone (Cooper et al. (2000) Bone 27: 375-381), and the 11 β-HSD1 inhibitor carbenoxolone has been shown to attenuate the negative effects of glucocorticoids on bone nodule formation (Bellows et al. (1998) Bone 23: 119-125). Thus, inhibition of 11β-HSD1 is predicted to decrease the local glucocorticoid concentration within osteoblasts and osteoclasts, thereby producing beneficial effects in various forms of bone disease, including osteoporosis.

As evidenced herein, there is a continuing need for new and improved drugs that inhibit 11 β-HSD1. The novel compounds of the instant invention are effective inhibitors of 11β-HSD1.

SUMMARY OF THE INVENTION

The present invention provides, inter alia, compounds of Formula I or pharmaceutically acceptable salts or prodrugs thereof, wherein constituent members are defined herein as follows:

wherein:

Q is NR ³ , O or S;

R ¹ is selected from the group consisting of (1) H; or (2) (C-CβJalkyl, (C ₃ -C ₇ )cycloalkyl, heterocyclyl, (C ₁ -C ₄ )alkoxy(C ₁ -C ₄ )alkyl, (C ₁ -

C ₄ )alkylthio(C _r C ₄ )alkyl, (C _r C ₄ )alkylsulfinyl(Ci-C4)alkyl, and (C ₁ -C ₄ )alkylsulfonyl(Ci-C ₄ )alkyl; or

(3) phenyl, phenyl(C _r C ₄ )alkyl, heteroaryl, and heteroaryl(d-C ₄ )alkyl;

X is independently selected from the group consisting of halogen, OH, CH ₂ OH, (Ci-C ₃ )alkyl, (Ci-C ₃ )haloalkyl, OR* , 0((C _r C ₃ )haloalkyl), CN, CH ₂ CN, NO ₂ , CH ₂ NO ₂ , SH, SR*, SO ₂ H, CH ₂ SO ₂ H, SO ₂ R*,CH ₂ SO ₂ R*, , SO ₂ NH ₂ , SO ₂ NHR*, SO ₂ NR* ₂ , CH ₂ SO ₂ NH ₂ , CH ₂ SO ₂ NHR*, CH ₂ SO ₂ NR* ₂ , SO ₂ CF ₃ , CH ₂ SO ₂ CF ₃ , CONH ₂ , CONHR*, CONR ^* ₂ , CH ₂ CONH ₂ , CH ₂ CONHR*, CH ₂ CONR* ₂ , CO ₂ H, CH ₂ CO ₂ H, NH ₂ , NHR*, NR ^* ₂ , (C _r C ₃ )alkyl(NH ₂ ), (Ci-C ₃ )alkyl(NHR*), (d-C^alkyKNR*,), aryl , heteroaryl and additionally SO ₃ H, CH ₂ SO ₃ H and heterocyclyl optionally substituted with alkyl, haloalkyl, hydroxy or oxo;

additionally, when R ¹ is heterocyclyl or heteroaryl, X can also be oxo, such that a carbonyl group or an N-oxide is formed;

m is O, 1 , 2 or 3;

R ² and R ³ are independently selected from the group consisting of (1) H; or (2) (CrC ₈ )alkyl, (C ₃ -C ₇ )cycloalkyl, heterocyclyl, (d-COalkoxy^-C^alkyl, (Ci-

C ₄ )alkylthio(C _r C ₄ )alkyl, (d-OOalkylsulfinyKd-OOalkyl, (C _r C ₄ )alkylsulfonyl(C _r C ₄ )alkyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, OH, (=0), CONH ₂ , CO ₂ H, COCH ₃ , C(O) ₂ CH ₃ , NH ₂ , NHR*, NR ^* ₂ , aryl , heteroaryl and additionally cyano, OR*, SR*, S(=O)R*, S(=O) ₂ R*, OP(=O)(OH) ₂ , NHSO ₂ R*, NR ^* SO ₂ R ^* , NHC(=O)R ^* , NR ^* C(=0)R ^* . NHC(=O)OR*, NR*C(=O)OR*. NHC(=O)NH ₂ , NHC(=O)NHR*, NHC(=O)N(R*) _2l NR*C(=O)NH ₂ , NR*C(=O)NHR*, NR*C(=0)N(R*) ₂ , OC(=O)NH ₂ , OC(=O)NHR ^* , OC(=O)N(R*) ₂ , NHS(=O) ₂ OR*, NR*S(=O) ₂ OR*, NHS(=O) ₂ NH ₂ , NHS(^O) ₂ NHR ^* , NHS(=O) ₂ N(R ^* ) ₂ , NR ^* S(=O) ₂ NH ₂ , NR*S(=O) ₂ NHR*. NR*S(=O) ₂ N(R*) ₂ , OS(=O) ₂ NH ₂ , OS(=O) ₂ NHR*, OS(=O) ₂ N(R*) ₂ , heterocyclyl; or (3) phenyl, phenyl(Ci-C ₄ )alkyl, heteroaryl, heteroaryl(Ci-C ₄ )alkyl optionally substituted with one to three substituents independently selected from the group consisting of OH, CH ₂ OH,

(Ci-C ₃ )alkyl, (C _r C ₃ )haloalkyl, OR* , O((C ₁ -C ₃ )haloalkyl), CN, CH ₂ CN, NO ₂ , CH ₂ NO ₂ , SH, SR ^* , SO ₂ H, CH ₂ SO ₂ H, SO ₂ R*,CH ₂ SO ₂ R*, , SO ₂ NH ₂ , SO ₂ NHR*, SO ₂ NR* ₂ , CH ₂ SO ₂ NH ₂ , CH ₂ SO ₂ NHR*, CH ₂ SO ₂ NR* _2l SO ₂ CF ₃ , CH ₂ SO ₂ CF ₃ , CONH ₂ , CONHR*, CONR* ₂ , CH ₂ CONH ₂ , CH ₂ CONHR*, CH ₂ CONR* ₂ , CO ₂ H, CH ₂ CO ₂ H, NH ₂ , NHR*. NR* ₂ , (C ₁ -C ₃ )BlKyI(NH ₂ ), (Ci-C ₃ )alkyl(NHR*), (d-C ₃ )alkyl(NR* ₂ ), aryl, heteroaryl, and additionally - SO ₃ H and CH ₂ SO ₃ H;

provided that

1) R ¹ and R ² are not both hydrogen when E is a bond; and 2) R ¹ is not hydrogen when m is greater than O;

each R* is independently d-C ₃ alkyl;

E is a bond, CH ₂ , CHMe, CMe ₂ , CH ₂ CH ₂ , OCH ₂ , OCHMe, OCMe ₂ , SCH ₂ , SCHMe, SCMe ₂ , provided that O and S are attached to R ¹ ;

G is a 1 , 2, or 3 carbon alkylene chain;

Y is independently selected from the group consisting of halogen, (CÏ„C ₃ )alkyl, CF ₃ , CONH ₂ , CH ₂ CONH ₂ , CO ₂ H, CH ₂ CO ₂ H, (C ₁ -C ₃ )alkylamino(C ₁ -C ₃ )alkyl and di(C ₁ -C ₃ )alkylamino(C ₁ - C ₃ )alkyl;

n is O, 1 , 2 or 3;

A is a bond, CH ₂ , CHMe, CMe ₂ , or CH ₂ CH ₂ ;

Cy is (C ₇ -C ₁₂ )bicycloalkyl or (C ₉ -C ₁₂ )tricycloalkyl in which 1-2 carbon atoms are optionally replaced with heteroatoms independently selected from N and O, and which is optionally substituted with 1 - 3 groups independently selected from halogen, cyano, (Ci-C ₃ )alkyl, halo(C ₁ -C ₃ )alkyl, hydroxy, hydroxy(C ₁ -C ₃ )alkyl, amino, (Ci-C ₄ )acylamino, (Ci-

C ₃ )alkylsulfonylamino, CH ₂ CH ₂ CO ₂ H, (C _r C ₃ )alkylcarbamoyl, di(C _r C ₃ )alkylcarbamoyl, (Ci- C ₃ )alkylaminosulfonyl, di(d-C ₃ )alkylaminosulfonyl, optionally substituted aryl, optionally substituted heteroaryl, oxo-substituted heteroaryl, amino-substituted heteroaryl, heterocyclyl, oxo-substituted heterocyclyl and C(=NOH)NH ₂ CON(R ⁴ ) ₂ , CH ₂ CON(R ⁴ ) ₂ , SO ₂ N(R ⁴ ) ₂ , CO ₂ R ⁴ , CH ₂ CO ₂ R ⁴ , SO ₂ R ⁴ , NR ⁴ COR ⁴ , NR ⁴ CO ₂ R ⁴ , NR ⁴ SO ₂ R ⁴ , and additionally OC(=O)N(R ⁴ ),

wherein each R ⁴ is independently hydrogen, (C ₁ -C ₁₀ ) alkyl, aryl or aralkyl. or an enantiomer, diastereomer, geometrical isomer or pharmaceutically acceptable salt thereof.

Preferably, for the compounds of Formula I, Q is O or NR ³ , and the values of the remaining variables are as described in Formula (I) More preferably, Q is NH or NMe, R ¹ is (d-C ₆ )alkyl, (C ₃ -C ₇ )cycloalkyl or phenyl, R ² is Me, G(Y) _n is CH ₂ or CH ₂ CH ₂ and Cy is 1- adamantyl, 2-adamantyl, 1-hydroxy-4-adamantyl, 1-hydroxymethyl-4-adamantyl, or 1- carbamoyl-4-adamantyl and the values of the remaining variables are as described in Formula (I). Alternatively, Q is O, R ¹ is (C _r C ₆ )alkyl, (C ₃ -C ₇ )cycloalkyl or phenyl, R ² is Me, G(Y) _n is CH ₂ or CH ₂ CH ₂ and Cy is 1-adamantyl, 2-adamantyl, 1-hydroxy-4-adamantyl, 1- hydroxymethyl-4-adamantyl, or 1-carbamoyl-4-adamantyl and the values of the remaining variables are as described in Formula (I).

In another preferred embodiment, the invention is a compound of Formula I ₁ wherein n is 0, and E is a bond and the values of the remaining variables are as described above. More preferably, R ¹ is tert-butyl.

In another embodiment, the invention is a compound of Formula I, wherein E is a bond, R ¹ is phenyl, X is fluorine and m is O ₁ 1 or 2, and values for the remainder of the variables are as described above for Formula (I).

In another embodiment, the invention is a compound of Formula I, wherein E is a bond, R ¹ is phenyl, X is monofluorophenyl or difluorophenyl and m is 1, and values for the remainder of the variables are as described above for Formula (I).

In another embodiment, the invention is a compound of Formula I, wherein E is a bond, R ¹ is phenyl, X is optionally substituted pyridyl or X is an oxo-substituted heterocyclyl optionally further substituted with alkyl, haloalkyl or hydroxy and m is 1 , and values for the remainder of the variables are as described above for Formula (I)

In another embodiment, the invention is a compound of Formula I, wherein R ² is hydroxy(C ₂ - C ₅ )alkyl, ω-H ₂ NC(=O)(C ₁ -C ₃ )alkyl, ω-MeSO ₂ NH(C _r C ₃ )alkyl or 2-(4-morpholino)ethyl, and values for the remainder of the variables are as described above for Formula (I)

In another preferred embodiment, the invention is a compound of Formula I wherein:

Q is NR ³ , or O;

R ³ is H, or (C-CβJalkyl;

E is a bond, CH ₂ , CHMe, CMe ₂ , or CH ₂ CH ₂ ;

R ¹ is H, (C ₁ -C ₈ )alkyl, (C ₃ -C ₇ )cycloalkyl, phenyl, phenyl(d-C ₄ )alkyl, heteroaryl, or heteroaryKCrCOalkyl;

X is F, Cl, Br, CN, OH, (Ci-C ₃ )alkyl, halo(d-C ₃ )alkyl, (C ₁ -C ₃ JaIkOXy, (d-CaJalkylsulfonyl, or CONH ₂ ;

m is O ₁ 1 , 2 or 3;

R ² is H, Me, Or CH ₂ OH;

provided that

1 ) R ¹ and R ² are not both hydrogen when E is a bond; and 2) R ¹ is not hydrogen when m is greater than O;

G(Y) _n is CH ₂ , CH(C ₁ -C ₃ )alkyl, C((C ₁ -C ₃ )alkyl) ₂ , or CH ₂ CH ₂ ;

n is O, 1 or 2;

A is a bond, CH ₂ ;

Cy is (C ₇ -C ₁₂ )bicycloalkyl and (C ₉ -Ci ₂ )tricycloalkyl in which 1 -2 carbon atoms are optionally replaced with heteroatoms independently selected from N and O, and which is optionally substituted with 1 - 3 groups independently selected from halogen, cyano, (CrC ₃ )alkyl, halo(CrC ₃ )alkyl, hydroxy, hydroxy(CrC ₃ )alkyl, amino, (Ci-C ₄ )acylamino, (Ci- C ₃ )alkylsulfonylamino, CH ₂ CH ₂ CO ₂ H, (Ci-C ₃ )alkylcarbamoyl, di(Ci-C ₃ )alkylcarbamoyl, (Ci- C ₃ )alkylaminosulfonyl, di(Ci-C ₃ )alkylaminosulfonyl, optionally substituted aryl, optionally substituted heteroaryl, oxo-substituted heteroaryl, amino-substituted heteroaryl, heterocyclyl, oxo-substituted heterocyclyl and C(=NOH)NH ₂ , CON(R ⁴ ) ₂ , CH ₂ CON(R ⁴ ) ₂ , SO ₂ N(R ⁴ ) ₂ , CO ₂ R ⁴ , CH ₂ CO ₂ R ⁴ , SO ₂ R ⁴ , NR ⁴ COR ⁴ , NR ⁴ CO ₂ R ⁴ , and NR ⁴ SO ₂ R ⁴ . Preferred

values for Cy are 1-adamantyl, 2-adamaπtyl, 1-hydroxy-3-adamantyl, 1-(hydroxymethyl)-3- adamantyl, 1-carbamoyl-3-adamantyl, 1-hydroxy-4-adamantyl, 1 -(hydroxy methyl)-4- adamantyl, i-carbamoyl-4-adamantyl, 1-bicyclo[2.2.2]octyl, 1-carbamoyl-4- bicyclo[2.2.2]octyl, 9-bicyclo[3.3.1]nonyl or 3-carbamoyt-9-bicyclo[3.3.1]nonyl;

each R ⁴ is independently hydrogen, (C ₁ -Ci ₀ ) alkyl, aryl or aralkyl;

or an enantiomer, diastereomer, geometrical isomer or pharmaceutically acceptable salt thereof.

More preferably, R ³ is H or Me; E is a bond or methylene; R ¹ is H, (C _r C ₈ )alkyl, or (C ₃ -C ₇ )cycloalkyl; X is Cl, Br or OH; m is 0 or 1; R ² is H, Me, or CH ₂ OH; G(Y) _n is CH ₂ , CHCH ₃ , or CH ₂ CH ₂ ; A is a bond or methylene; and Cy is 1-adamantyl, 2-adamantyl, 1- hydroxy-4-adamantyl, 1-hydroxymethyl-4-adamantyl, or 1-carbamoyl-4-adamantyl. The values of the remaining variables are as described above. More preferred are compounds of Formula I wherein:

Q is NR ³ , or O;

R ³ is H ₁ or Me;

E is a bond, or CH ₂ ;

R ¹ is H, methyl, ethyl, isopropyl, isobutyl, tert-butyl, cyclohexyl, or Ph;

X is Cl, Br, or OH;

m is 0 or 1 ;

R ² is H, Me, or CH ₂ OH;

G(Y) _n is CH ₂ , CHMe, or CH ₂ CH ₂ ;

n is 0 or 1 ;

A is a bond, or CH ₂ ;

Cy is 1-adamantyl, 2-adamantyl, or 1-hydroxy-4-adamantyl;

or an enaπtiomer, diastereomer, geometrical isomer or pharmaceutically acceptable salt thereof.

Specifically preferred compounds of the Formula I are:

(S)-3-((1-adamantyl)rnethyl)-5-phenyloxazolidin-2-one; (S)-3-((1 -adamantyl)methyl)-5-isobutyloxazolidin-2-one;

(S)-3-(1-adamantyl)-5-isobutyloxazolidin-2-one;

(S)-3-(2-adamantyl)-5-isobutyloxazolidin-2-one;

(S)-3-((1-adamantyl)methyl)-5-(2-chlorophenyl)oxazolidin- 2-one;

(S)-3-((1-adamantyl)methyl)-5-(t-butyl)oxazolidin-2-one; (S)-3-(2-adamantyl)-5-tert-butyloxazolidin-2-one;

(S)-3-(2-adamantyl)-5-methyl-5-phenyloxazolidin-2-one;

(S)-3-((1-adamantyl)methyl)-5-cyclohexyloxazolidin-2-one;

(S)-3-(2-adamantyl)-5-cyclohexyloxazolidin-2-one;

(R)-3-(2-adamantyl)-5-cyclohexyloxazolidin-2-one; (4R,5S)-3-((1-adamantyl)methyl)-4-methyl-5-phenyloxazolidin- 2-one;

(S)-1-(2-adamantyl)-4-tert-butylimidazolidin-2-one;

(S)-1-(2-adamantyl)-3-methyl-4-tert-butyl-imidazolidin-2- one;

5-(4-bromophenyl)-3-(2-adamantyl)oxazolidin-2-one;

(S)-1-(1-adamantyl)-4-phenylimidazolidin-2-one 4-tert-butyl-1-(2-adamantyl)tetrahydropyrimidin-2(1 H)-one

(S)-4-cyclohexyl-1-(2-adamantyl)imidazolidin-2-one

(S)-4-isopropyl-1-(2-adamantyl)imidazolidin-2-one

5-(3-bromophenyl)-3-(2-adamantyl)oxazolidin-2-one

1-(2-adamantyl)-4-(hydroxymethyl)-4-isobutylimidazolidin- 2-one 5-(biphenyl-3-yl)-3-(2-adamantyl)oxazolidin-2-one

5-(biphenyl-4-yl)-3-(2-adamantyl)oxazolidin-2-one

or an enantiomer, diastereomer, geometrical isomer or pharmaceutically acceptable salts thereof.

The present invention further provides methods of inhibiting 11β-HSD1 by contacting 11β-HSD1 with a compound of Formula I of the invention.

The present invention further provides methods of inhibiting the conversion of cortisone to Cortisol in a cell using a compound of Formula I of the invention.

The present invention further provides methods of inhibiting production of Cortisol in a cell using a compound of Formula I of the invention.

The present invention further provides methods of increasing insulin sensitivity using a compound of Formula I of the invention.

The present invention further provides methods of preventing or treating diseases associated with activity of expression of 11β-HSD1 using a compound of Formula I of the invention.

DETAILED DESCRIPTION OF THE INVENTION

Definitions:

The term "alkyl" means a straight or branched hydrocarbon radical having 1-10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.

The term "cycloalkyl" means a saturated hydrocarbon ring having 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.

The term "bicycloalkyl" means two saturated hydrocarbon rings having a total of 7- 12 carbon atoms which are joined by 1 ,1 -fusion, 1,2-fusion or 1 ,n-fusion to give spirocyclic ring systems, fused ring systems and bridged ring systems respectively. Spirocyclic ring systems include, for example, spiro[2.4]heptane, spiro[2.5]octane, spiro[4.4]Ï€onane, spiro[4.5]decane, spiro[5.5]undecane and the like. Fused ring systems include, for example, bicyclo[4.1.0]heptane, octahydro-1H-indene, decahydronaphthalene and the like. Bridged ring systems include for example, bicyclo[3.3.1]nonane, bicyclo[2.2.2]octane, bicyclo[2.2.1]heptane and the like.

The term "tricycloalkyl" means three saturated hydrocarbon ring having a total of 9- 12 carbon atoms which are joined by any combination of 1 ,1-fusion, 1 ,2-fusion or 1 ,n-fusion and includes, for example, adamantyl, noradamantyl and the like.

The terms "alkoxy" and "thioalkoxy" are O-alkyl or S-alkyl of from 1-6 carbon atoms.

The term "aryl" means an aromatic radical which is a phenyl group, a phenylalkyl group, a phenyl group substituted with 1-4 substituents selected from alkyl, alkoxy, thioalkoxy, alkylsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO ₂ H, CONH ₂ , N-monoalkyl-substituted amido and N,N-dialkyl-substituted amido.

The term "heteroaryl" means a 5- and 6-membered heteroaromatic radical which may optionally be fused to a ring containing 1-4 heteroatoms selected from N, O, and S and includes, for example, a heteroaromatic radical which is 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3- pyrrolyl, 2-,3-, or 4-pyridinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 3- or 4-pyridazinyl, 1 H- indol-6-yl, 1H-indol-5-yl, 1 H-benzimidazol-6-yl, 1H-benzimidazol-5-yl, 2-, 4-, or 5-thiazolyl, 3- , 4-, or 5-pyrazolyl, 2-, 4-, or 5-imidazolyl and the like optionally substituted by a substituent selected from alkyl, alkoxy, thioalkoxy, alkylsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO ₂ H, CONH ₂ , N-monoalkyl-substituted amido and N,N-dialkyl-substituted amido, or by oxo to form an N-oxide.

The term "heterocyclyl" means a 4-, 5-, 6- and 7-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S, and include pyrrolidine, piperidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, isoxazolidine, 1 ,3-dioxolane, 1,3-dithiolane, 1 ,3- dioxane, 1 ,4-dioxane, 1 ,3-dithiane, 1,4-dithiane, morpholine, thiomorpholine, thiomorpholine 1 ,1 -dioxide, tetrahydro-2H-1 ,2-thiazine 1 ,1 -dioxide, and isothiazolidine 1 ,1 -dioxide and azetidine. The term "oxo-substituted heterocyclyl" means a 4-, 5-, 6- and 7-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S, and include pyrrolidin-2-one, piperidin-2-one, 1 ,2- dihydro-2-oxopyridine, 3,4-dihydro-4-oxopyrimidine, tetrahydropyrimidin-2(1H)-one. As such, a heterocyclyl substituted at a ring carbon with oxo forms a ketone at said position; and a heterocyclyl substituted at a ring nitrogen with oxo forms an n-oxide at said position. A heterocyclyl group can be optionally substituted with 1-4 substituents. Exemplary substituents include oxo, alkyl, haloalkyl and hydroxy.

The term "adamantyl" means an adamantane moiety bonded to another atom via the 1- or 2- position of adamantane. Examples of suitable adamantyl groups include 1- adamantyl, 2-adamantyl, 1-hydroxy-3-adamantyl, 1-(hydroxymethyl)-3-adamantyl, 1- carbamoyl-3-adamantyl, 1-hydroxy-4-adamantyl, 1-(hydroxymethyl)-4-adamantyl, 1- carbamoyl-4-adamantyl, 1-bicyclo[2.2.2]octyl, 1-carbamoyl-4-bicyclo[2.2.2]octyl, 9- bicyclo[3.3.1]nonyl or 3-carbamoyl-9-bicyclo[3.3.1]nonyl;

The term "mammal" as used herein includes all mammals, including, but not limited to, humans.

As used herein the terms "subject" and "patient" may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like). Typically, the subject is a human in need of treatment.

As used herein, the term "treating" or 'treatment" refers to obtaining desired pharmacological and/or physiological effect. The effect can be prophylactic or therapeutic, which includes achieving, partially or substantially, one or more of the following results: partially or totally reducing the extent of the disease, disorder or syndrome; ameliorating or improving a clinical symptom or indicator associated with the disorder; delaying, inhibiting or decreasing the likelihood of the progression of the disease, disorder or syndrome; or partially or totally delaying, inhibiting or reducing the likelihood of the onset or development of disease, disorder or syndrome. When a disclosed compound or its pharmaceutically acceptable salt is named or depicted by structure, it is to be understood that solvates or hydrates of the compound or its pharmaceutically acceptable salts are also included. "Solvates" refer to crystalline forms wherein solvent molecules are incorporated into the crystal lattice during crystallization. Solvate may include water or nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and EtOAc. Solvates, wherein water is the solvent molecule incorporated into the crystal lattice, are typically referred to as "hydrates." Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water.

Certain of the disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center.

"Enantiomer" means one of a pair of molecules that are mirror images of each other and are not supeπmposable Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms The symbol "*" in a structural formula represents the presence of a chiral carbon center "R' and "S" represent the configuration of substituents around one or more chiral carbon atoms Thus, "R*" and "S ^* " denote the relative configurations of substituents around one or more chiral carbon atoms

"Racemate" or "racemic mixture" means a compound of equimolar quantities of two enantiomers, wherein such mixtures exhibit no optical activity, i e , they do not rotate the plane of polarized light

"Geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration

"R," "S," "S*," "R*," "E," "Z," "cis," and "trans," indicate configurations relative to the core molecule

The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting material or a final product using various well known chromatographic methods

When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99 9% by weight pure relative to the other stereoisomers When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99 9% by weight optically pure Percent optical purity by weight is the ratio of the weight of the enantiomer over the weight of the enantiomer plus the weight of its optical isomer When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has at least one chiral center, it is to be

understood that the name or structure encompasses one enantiomer of compound free from the corresponding optical isomer, a racemic mixture of the compound and mixtures enriched in one enantiomer relative to its corresponding optical isomer

When a disclosed compound is named or depicted by structure without indicating the stereochemistry and has at least two chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other diastereomers, a pair of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other dιastereomer(s) and mixtures of diastereomeric pairs in which one diastereomeric pair is enriched relative to the other diastereomeric paιr(s)

The compounds of the invention may be present in the form of pharmaceutically acceptable salts For use in medicines, the salts of the compounds of the invention refer to non-toxic "pharmaceutically acceptable salts " Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamme, piperazine and tπethanolamine salts

Pharmaceutically acceptable acidic/anionic salts include, the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, malonate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphospate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, hydrogensulfate, tannate, tartrate, teoclate, tosylate, and tπethiodide salts

The following abbreviations have the indicated meanings

Abbreviation Meaning

Boc te/t-butoxy carbonyl or f-butoxy carbonyl

(BoC) ₂ O di-fert-butyl dicarbonate

Cbz Benzyloxycarbonyl

CbzCI Benzyl chloroformate

DAST diethylaminosulfur trifluoπde

DBU 1,8-dιazabιcyclo[5 4 0]undec-7-ene

DCC N.N'-dicyclohexylcarbodiimide

DCU N,N'-dιcyclohexylurea

DIAD diisopropyl azodicarboxylate

DIEA N,N-dιιsopropylethylamιne

DMAP 4-(dιmethylamιno)pyrιdιne

DMF N,N-dιmethylformamιde

DMPU 1 ,3-dιmethyl-3,4,5,6-tetrahydro-2(1 H)-pyrιmιdιnone

2,4-DNP 2,4-dιnιtrophenylhydrazιne

DPTBS Diphenyl-t-butylsilyl

EDC HCI, EDCI 1-[3-(dιmethylamιno)propyl]-3-ethylcarbodιιmιde hydrochloride

Eq u iv equivalents

Fmoc 1-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-

Fmoc-OSu 1-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-2,5-pyrrolιdιned ιone h, hr hour(s)

HOBt 1 -hydroxy benzotriazole

HATU 2-(7-Aza-1 H-benzotrιazole-1-yl)-1 ,1 ,3 3-tetramethyluronιum hexafluorophosphate

HBTU 2-(1 H-Benzotπazol-1-yl)-1 , 1 ,3,3-tetramethyluronιum hexafluorophosphate

KHMDS potassium hexamethyldisilazane

LAH or LiAIH ₄ lithium aluminum hydride

LC-MS liquid chromatography-mass spectroscopy

LHMDS lithium hexamethyldisilazane

Me methyl

MsCI methanesulfonyl chloride

Mm minute

MS mass spectrum

NaH sodium hydride

NaHCO ₃ sodium bicarbonate

NaN ₃ sodium azide

NaOH sodium hydroxide

Na ₂ SO ₄ sodium sulfate

NMM N-methylmorpholine

NMP N-methylpyrrolidinone

Pd ₂ (dba) ₃ trιs(dιbenzylιdeÏ€eacetone)dιpalladιum(0)

PE petroleum ether

Quant quantitative yield

Satd saturated

SOCI ₂ thionyl chloride

SPA scintillation proximity assay

SPE solid phase extraction

TBAF tetrabutylammonium fluoride

TBS t-butyldimethylsilyl

TBDPS t-butyldiphenylsilyl

TBSCI t-butyldimethylsilyl chloride

TBDPSCI t-butyldiphenylsilyl chloride

TEA tÏ€ethylamine or Et ₃ N

TEMPO 2 2,6,6-tetramethyl-1-pιpeπdιnyloxy free radical

Teoc 1 -[2-(tπmethylsιlyl)ethoxycarbonyloxy]-

Teoc-OSu 1-[2-(trιmethylsιlyl)ethoxycarbonyloxy]pyrrolιdιn-2,5-dÎ ¹one

TFA trifluoroacetic acid

TIc, TLC thin layer chromatography

TMS trimethylsilyl

TMSCI chlorotrimethylsilane or trimethylsilyl chloride t _R retention time

TsOH p-toluenesulfonic acid

GENERAL DESCRIPTION OF SYNTHESIS

Compounds of the Formula I can be prepared by several processes In the discussion below R ¹ - R ³ , A, Cy, E, G, Q, X, Y, m and n have the meanings indicated above unless otherwise noted In cases where the synthetic intermediates and final products of Formulas I described below contain potentially reactive functional groups, for example amino, hydroxyl, thiol and carboxylic acid groups, that may interfere with the desired reaction, it may be advantageous to employ protected forms of the intermediate Methods for the selection, introduction and subsequent removal of protecting groups are well known to those skilled in the art (T W Greene and P G M Wuts "Protective Groups in Organic Synthesis" John Wiley & Sons, lnc , New York 1999) Such protecting group manipulations are assumed in the discussion below and not described explicitly Generally, reagents in the reaction schemes are used in equimolar amounts, however, in certain cases it may be desirable to use an excess of one reagent to drive a reaction to completion This is especially the case when the excess reagent can be readily removed by evaporation or extraction Bases employed to neutralize HCI in reaction mixtures are generally used in slight to substantial excess (1 05 - 5 equivalents) In the first process a compound of Formula I can be prepared by reaction of an intermediate of Formula Il with a reagent of Formula III, wherein Z ¹ and Z ² are leaving groups such as chloride, 1-ιmιdazolyl or aryloxide in an inert solvent such as THF, CH ₂ CI ₂ , toluene or MeCN ₁ usually in the presence of an organic or inorganic base such as triethylamine or NaHCO ₃ respectively, at -10 ⁰ C to 120 ⁰ C

Il IM I

Certain instances of reagent III are especially convenient because they are commercially available. For example when Z ¹ and Z ² are both chloride, III is phosgene. When Z ¹ and Z ² are both 1-imidazolyl, III is carbonyl diimidazole. When Z ¹ is chloride and Z ² is p- nitrophenoxide, III is p-nitrophenyl chloroformate. When Z ¹ and Z ² are both OCCI ₃ , III is triphosgene and as little as one third of molar equivalent can be used.

Intermediates of Formula Il wherein Q is O, G is CH ₂ and n is 0 can be prepared by reduction of amides of Formula IV using a hydride reagent such as BH ₃ THF solution, BH ₃ -Me ₂ S or LiAIH ₄ in an inert solvent ethereal such as THF or DME at 20 ⁰ C to 100 ⁰ C for between 1 h and 48 h:

IV Il

G = CH ₂ , n = 0

Intermediates of Formula IV can be prepared by coupling of an α-hydroxyacid of Formula V with an amine of Formula Vl using standard peptide coupling reagents such as EDC in the presence of HOBt and N,N-diisopropylethylamine in an inert solvent such as CH ₂ CI ₂ at 0 - 30 ⁰ C for between 1 h and 24 h:

V Vl IV

Certain α-hydroxyacids of Formula V are commercially available. α-Hydroxyacids of Formula V can be prepared by diazotization of α-amino acids of Formula VII using NaNO ₂ in H ₂ SO ₄ :

VII V α-Hydroxyacids of Formula V can also be prepared from ketones Formula VIII via cyanohydrins of Formula IX:

VIII IX V Methods for the conversion of ketones to cyanohydrins are described in Smith, M. B. and March, J. "March's Advanced Organic Chemistry" pp 1239-1240, 5 ^th Edition, Wiley, New York, NY, 2001. Methods for the hydrolysis of cyanohydrins to α-hydroxyacids are described in Smith, M. B. and March, J. "March's Advanced Organic Chemistry" p 1179, 5 ^th Edition, Wiley, New York, NY, 2001 α-hydroxyacids of Formula V, wherein R ¹ is not H when E is a bond and R ² is not H, can also be prepared by oxidation of diols of Formula X with for example oxygen in the presence of a catalyst or using sodium chlorite and TEMPO:

X V

Amine intermediates of Formula Vl wherein A is CH ₂ can be prepared by reduction of amides of Formula Xl using a hydride reagent such as BH ₃ THF solution, BH ₃ -Me ₂ S or LiAIH ₄ in an inert solvent ethereal such as THF or DME at 20 ⁰ C to 100 ⁰ C for between 1 h and 48 h:

H ₂ y ^{' H>N'AX} "

Xl Vl

A = CH ₂

Amine intermediates of Formula Vl wherein A is a bond can be prepared from ketones of formula XII via oximes of Formula XIII:

O NOH λ

Cy Cy " H ₂ N' ^Cy

XII XIII Vl

A = bond

Methods for the conversion of ketones to oximes are described in Smith, M. B. and March, J. "March's Advanced Organic Chemistry" pp 1194-1195, 5 ^th Edition, Wiley, New York, NY, 2001. Methods for the reduction of oximes to primary amines are described in Smith, M. B. and March, J. "March's Advanced Organic Chemistry" p 1555, 5 ^th Edition, Wiley, New York, NY, 2001.

Intermediates of Formula Il wherein Q is O ₁ G is CH ₂ and n is 0 can be prepared by reaction of epoxides of Formula XIV with amines of Formula Vl as described in Smith, M. B. and March, J. "March's Advanced Organic Chemistry" p 504, 5 ^th Edition, Wiley, New York, NY, 2001 :

XIV Vl Il

Q = O, G = CH ₂ , n = 0

Epoxide compounds of formula XIV can, in turn, be prepared in a number of ways including, as described in Aube, J. "Epoxidation and Related Processes" Chapter 3.2 in Volume 1 of

"Comprehensive Organic Synthesis" Edited by B. M. Trost, I. Fleming and Stuart L.

Schreiber, Pergamon Press, New York, 1992).

Analogously intermediates of Formula Il wherein G is CH ₂ CH ₂ can be prepared by reaction of oxetanes of Formula XV with amines of Formula Vl as described in Smith, M. B. and March, J. "March's Advanced Organic Chemistry" p 505, 5 ^th Edition, Wiley, New York,

NY, 2001 :

XV Vl Il

Q = O ₁ G = CH ₂ CH ₂ , n = 0

Intermediates of Formula Il wherein A is CH ₂ can be prepared by reduction of amide intermediates of formula XVI using a hydride reagent such as BH ₃ THF solution, BH ₃ . Me ₂ S or LiAIH ₄ in an inert solvent ethereal such as THF or DME at 20 ⁰ C to 100 ⁰ C for between 1 h and 48 h:

xvi Ii

Q = O, A = CH ₂

Amide intermediates of Formula XVI can be prepared by reaction of an amino- alcohol intermediate of Formula XVII with activated carboxylic acid of Formula XVIII wherein Z ³ is chloride or an activated ester, such as an N-hydroxysuccinimide ester:

XVII XVIII XVI

Amino-alcohol intermediates of Formula XVII wherein G is CH ₂ and n is 0 can be prepared by reaction of an epoxide of Formula XIV with azide ion to give an azido-alcohol of Formula XIX followed by reduction of the azide moiety with hydrogen gas or using triphenylphosphine in the presence of water:

XIV XIX XVII G = CH ₂ , n = 0

Amino-alcohol intermediates of Formula XVII wherein G is CH ₂ CH ₂ and n is 0 can be prepared by reaction of an epoxide of Formula XIV with cyanide ion followed by reduction of the resulting hydroxynitrile of Formula XX with hydrogen gas in the presence of a catalyst or with a hydride source such as LiAIH ₄ :

XIV XX XVII

G = CH ₂ CH ₂ , n = 0

Intermediates of Formula Il wherein Q is N, R ³ is H, G is CH ₂ and n is 0 can be prepared by reduction of α-aminoamides of Formula XXI using a hydride reagent such as BH ₃ THF solution, BH ₃ . Me ₂ S or LiAIH ₄ in an inert solvent ethereal such as THF or DME at 20 ⁰ C to 100 ⁰ C for between 1 h and 48 h:

XXI Il

Q = NR ³ , G = CH ₂ , n = 0 α-Aminoamides of Formula XXI can be prepared by coupling of a suitably N- protected α-amino-acid of Formula XXII with an amine of Formula Vl using standard peptide coupling reagents such as EDC with HOBt or HATU in the presence of N ₁ N- diisopropylethylamine in an inert solvent such as CH ₂ CI ₂ at 0 - 30 ⁰ C for between 1 h and 24 h followed by removal of the protecting group:

XXII Vl XXI

PG = protecting group

Intermediates of Formula Il wherein Q is N, R ³ is Me, G is CH ₂ and n is 0 can be prepared by reduction of α-(tert-butoxycarbonylamino)amides of Formula XXIII using LiAIH ₄ in an inert solvent ethereal such as THF or DME at reflux for between 6 h and 72 h:

XXIII Il

Q = NMe, G = CH ₂ , n = 0

Intermediates of Formula Il wherein Q is N, R ³ is H, G is CH ₂ CH ₂ and n is 0 can be prepared by reduction of β-aminoamides of Formula XXIV using a hydride reagent such as BH ₃ THF solution, BH ₃ -Me ₂ S or LiAIH ₄ in an inert solvent ethereal such as THF or DME at 20 ⁰ C to 100 ⁰ C for between 1 h and 48 h:

XXIV Il

Q = NR ³ , G = CH ₂ CH ₂ , n = 0

Intermediates of Formula Il can be prepared by ring opening of aziridines of Formula XXV wherein PG is a protecting group such as Boc or Ts with amines of Formula Vl followed by removal of PG:

XXV Vl Il Q = NH, G = CH ₂ , n = 0

Intermediates of Formula Il wherein G is CH ₂ and n is 0 can also be prepared by reductive amination of aldehyde intermediates of Formula XXVI with amines of Formula Vl using for example NaCNBH ₃ or NaBH(OAc) ₃ as reducing agent:

XXVI Vl I,

G = CH ₂ , n = 0

Additional methods for the synthesis of 1 ,2-diamine intermediates of Formula Il wherein Q = NR ³ are described in Lucet, D.; Le Gall, T.; Mioskowski, C. Angew. Chem. Int. Ed. 1998, 37, 2580-2617.

In the second process a compound of Formula I wherein Q is O can be prepared by reaction of a carbamate intermediate of Formula XXVII wherein R ^a is alkyl or benzyl with an epoxide intermediate of Formula XIV in the presence of a strong base such as NaH in a solvent such as THF or DMF at 0 °C to 80 ⁰ C:

xiv xxvii i

Carbamate intermediates of Formula XXVII can be prepared by reaction of amines of Formula Vl with chloroformates of Formula XXVIII in the presence of a base such as pyridine or triethylamine in an inert solvent such as CH ₂ CI ₂ or THF at 0 ⁰ C to 25 ⁰ C for between 1 h and 24 h:

vi XXViIi XXVII

In the third process of the invention a compound of Formula I can be prepared from another compound of Formula I. For example:

(1) a compound of Formula I wherein Cy bears a CO ₂ H substituent can be converted to the corresponding acid chloride by treatment with SOCI ₂ or (COCI) ₂ and then reacted with ammonia to give a compound of Formula I wherein Cy bears a CONH2 substituent.

(2) a compound of Formula I wherein Cy bears a CONH ₂ substituent can be treated with a dehydrating agent such as (CF ₃ CO) ₂ O or POCI ₃ to convert it to a compound of

Formula I wherein Cy bears a CN substituent.

(3) a compound of Formula I wherein Cy bears a CO ₂ Me substituent can be reduced with for example LiBH ₄ or LiAIH ₄ in THF to give a compound of Formula I wherein Cy bears a CH ₂ OH substituent. (4) a compound of Formula I wherein Cy bears a CO ₂ Me substituent can be reacted with an excess of MeLI or MeMgBr to give a compound of Formula I wherein Cy bears a C(CH ₃ ) ₂ OH substituent.

(5) a compound of Formula I wherein Q is NR ³ and R ³ is H can be reacted with a strong base such as NaH followed by an (C ₁ -C ₈ )BIkVl hahde, a (CrC ₄ )alkoxy(Ci-C4)alkyl halide or a phenyl(CÏ„C ₄ )alkyl hahde to give a compound of Formula I wherein Q is NR ³ and R ³ is (Ci-C ₈ )alkyl, (C ₁ -C ₄ )alkoxy(C ₁ -C ₄ )alkyl or phenyl^-C^alkyl

(6) a compound of Formula I wherein R ¹ is aryl or heteroaryl and X is bromine or iodine can be reacted with an aryl or heteroarylboronic acid or ester in the presence of a palladium catalyst to give a compound of Formula I wherein R ¹ is aryl or heteroaryl and X is aryl or heteroaryl

Purification Methods

Compounds of the invention may be purified by high pressure liquid chromatography (HPLC) using the following conditions Unless otherwise specified, prep HPLC refers to preparative reverse phase HPLC on a C-18 column eluted with a water/acetonitrile gradient containing 0 01% TFA run on a Gilson 215 system

Analytical Methods LC-MS (3 mm)

Column Chromolith SpeedRod, RP-18e, 50 x 4 6 mm, Mobil phase A 0 01%TFA/water, B 0 01%TFA/CH ₃ CN, Flow rate 1 mL/min, Gradient

LC-MS (4 mm)

Column YMC ODS-AQ, S-5mm, 12nm, 50 x 2 0 mm ID, Column temperature 40 °C, Mobil phase A H2O+ 0 1% TFA, B MeCN+ 0 05% TFA, Flow rate 0 8 mL/min, Gradient

Time (min) A% B%

0 00 100 0

0 4 100 0

2 00 40 60

2 50 40 60

2 51 100 0

4 00 100 0

LC-MS (16 mm)

Column Chromolith SpeedRod, RP-18e, 50 x 4 6 mm, Mobil phase A 0 01%TFA/water, B

0 01%TFA/CH ₃ CN, Flow rate 1 mL/min, Gradient

EXAMPLES

Example 1 (S)-3-((1-adamantyl)methyl)-5-phenyloxazolιdιn-2-one

Step 1

Adamantane-1-carboxylιc acid (10 g, 55 mmol) was heated at reflux with thionyl chloride (15 mL) and dimethylformamide (1 drop) for 2 h under an inert atmosphere

Excess thionyl chloride was distilled off under vacuum. The residue was dissolved in THF (30 mL) and added to a solution of concentrated aqueous ammonia (135 ml_) at 0 ⁰ C. The reaction was stirred for 2 h at rt. The mixture was cooled to 10 ⁰ C and filtered to give the crude product, which was washed with water and dried to afford admantane-1-carboxamide (6.6 g, 67%). ¹ H NMR (CDCI ₃ , 400 MH _Z ): δ=1.71-2.04 (t, 15H), 5.66-5.75 (d, 2H).

Step 2

To a solution of admantane-1 -carboxamide (2 g, 11.17 mmol) in THF (50 mL) was added BH ₃ . Me ₂ S (10.2 M, 3.4 mL, 34.7 mmol) under nitrogen. The mixture was heated at reflux overnight. The solution was cooled to rt. Methanol (20 mL) was added to the solution. The mixture was concentrated under vacuum to give crude product, which was purified by chromatography on silica gel to afford (i-adamantyl)methylamine (1.09 g, 59 %). ¹ H NMR (CDCI ₃ , 400 MH _Z ): δ=1.44-1.96 (m, 15H), 2.30 (s, 2H).

Step 3

To a solution of (i-adamantyl)methylamine (100 mg, 0.61 mmol), (S)-2-hydroxy-2- phenylacetic acid (92 mg, 0.61 mmol), EDCI (239 mg, 1.22 mmol) and HOBt (164 mg, 1.22 mmol) in CH ₂ CI ₂ (15 mL) was added DIEA (391 mg, 3.03 mmol) and the resulting mixture was stirred overnight. The solution was concentrated under vacuum to give the crude product, which was purified by preparative TLC to afford (S)-N-((1-adamantyl)methyl)-2- hydroxy-2-phenylacetamide (85 mg, 47%). ¹ H NMR (CDCI ₃ , 400 MH _Z ): 5=1.34-1.91 (m, 15H), 2.86 (q, 1 H), 3.02 (q, 1 H), 5.04 (s, 1 H), 5.93 (s, 1 H), 7.25-7.43 (m, 5H).

Step 4 To a solution of (S)-N-((1-adamantyl)methyl)-2-hydroxy-2-phenylacetamide (85 mg,

0.28 mmol) in THF (10 mL) was added BH ₃ .Me ₂ S (10 M, 85 μL, 8.5 mmol) under nitrogen. The mixture was heated under reflux overnight and then cooled to rt. The reaction was quenched with methanol. The mixture was concentrated in vacuum to give crude product, which was purified by preparative TLC to afford (S)-2-((1-adamantylmethyl)amino)-1- phenylethanol (40 mg, 50%). ¹ H NMR (MeOD, 400 MH _Z ): 5=1.31-2.01 (m, 15H), 2.42 (q, 2H), 2.81 (d, 2H), 4.88 (t, 1H), 7.21-7.43(m, 5H).

Step 5

To a solution of (S)-2-((1-adamantylmethyl)amino)-1 -phenylethanol (35 mg, 0.12 mmol), Et ₃ N (24.8 mg, 0.25 mmol) in CH ₂ CI ₂ (2 mL) at 0 ⁰ C was added triphosgene (14.6 mg, 0.05 mmol) and the mixture was stirred for 30 min. The mixture was concentrated

under vacuum to give the crude product, which was purified by preparative TLC to give (S)- 3-((1-adamantyl)methyl)-5-phenyloxazolidin-2-one (10 mg, 26%). ¹ H NMR (MeOD, 400 MHz): 5=1.51-1.95 (m, 15H), 2.89 (q, 2H), 3.55 (q, 1 H), 4.10 (t, 1H), 5.57 (q, 1 H), 7.34-7.45 (m, 5H); MS m/z = 312.

Example 2 (S)-3-((1-adamantyl)methyl)-5-isobutyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 1 using (S)-2-hydroxy-4-methylpentanoic acid in Step 3. ¹ H NMR (MeOD, 400 MH _Z ): δ 0.97 (d, 6H),1.40-1.97 (m, 18H), 2.81 (dd, 2H), 3.78 (t, 1H), 4.63 (m, 1 H); MS m/z = 292

Example 3 (R)-3-((1-adamantyl)methyl)-5-phenyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 1 Steps 3 - 5 using (R)-2-hydroxy-2-phenylacetic acid in Step 3. ¹ H NMR (MeOD, 400 MH _Z ): δ 1.62 (m, 6H), 1.64-1.96 (m, 6H), 2.05 (m, 3H), 3.01 (m, 2H), 3.65 (m, 1 H) ₁ 4.19 (m, 1 H), 5.66 (m, 1 H),7.49 (m, 5H); MS m/z = 312.

Example 4 (S)-3-(1-adamantyl)-5-isobutyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 1 Steps 3 - 5 using (S)-2-hydroxy-4-methylpentanoic acid and 1- aminoadamantaÏ€e in Step 3. ¹ H NMR (MeOD, 400 MH ₂ ): δ 0.99(d, 6H), 1.46(m, 1 H), 1.59- 1.90(m,9H), 2.11(m, 9H), 3.25(m, 1 H), 3.78(t, 1H), 4.49(m, 1 H); MS m/z = 278

Example 5

(S)-3-(2-adamantyl)-5-isobutyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 1 Steps 3 - 5 using (S)-2-hydroxy-4-methylpentanoic acid and 2- aminoadamantane hydrochloride in Step 3. ¹ H NMR (MeOD, 400 MH _Z ): δ 0.98(d, 6H),

1.49(m, 1H), 1.61-2.02(m, 14H) ₁ 2.28(m, 1 H), 2.40(m, 1 H), 3.36(m, 1H), 3.65(m, 1 H), 3.90(t, 1H), 4.61 (m, 1H); MS m/z = 278

Example 6 (S)-5-benzyl-3-((1 -adamantyl)methyl)oxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 1 using (S)-2-hydroxy-3-phenylpropanoic acid in Step 3. ¹ H NMR (MeOD, 400 MH _Z ): δ 1.39(m, 6H), 1.64(m, 6H), 1.90(m, 3H), 2.72(dd, 2H), 3.00(m, 2H), 3.42(m, 1H), 3.67(t, 1H), 4.75(m, 1 H), 7.29(m, 5H); MS m/z = 326

Example 7 (S)-3-((1-adamantyl)methyl)-5-(2-chlorophenyl)oxazolidin-2-o ne

The title compound was prepared following procedures analogous to those described in Example 1 using (S)-2-(2-chlorophenyl)-2-hydroxyacetic acid in Step 3. ¹ H NMR (MeOD, 400 MH _Z ): δ 1.50(m, 6H), 1.62(m, 6H), 1.92(m, 3H) ₁ 2.90(m, 2H), 3.51 (m, 1 H), 4.23(m, 1H), 5.84(m, 1 H), 7.46(m, 4H); MS m/z = 346

Example 8

(S)-3-((1-adarnantyl)methyl)-5-(t-butyl)oxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 1 using (S)-2-hydroxy-3,3-dimethylbutanoic acid in Step 3. ¹ H NMR (MeOD, 400 MH _Z ): δ 0.95 (s, 9H), 1.58 (m, 6H), 1.72 (m, 6H), 1.99 (m, 3H), 2.88 (dd, 2H), 3.48(m, 1H), 3.66(m, 1H), 4.28(m, 1 H); MS m/z = 292

Example 9

(±)-3-((1-adamantyl)methyl)-5-(3-chlorophenyl)oxazolidin -2-one

The title compound was prepared following procedures analogous to those described in Example 1 using 2-(3-chlorophenyl)-2-hydroxyacetic acid in Step 3. ¹ H NMR (MeOD, 400 MHz): δ 1.48-1.85 (m, 12H), 1.95 (m, 3H), 2.90 (m, 2H), 3.52 (m, 1 H), 4.11 (m, 1 H), 5.56 (m, 1 H), 7.29-7.48 (m, 4H); MS m/z = 346.

Example 10 (S)-3-((1-adamantyl)methyl)-5-ethyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 1 using (S)-2-hydroxybutanoic acid in Step 3. ¹ H NMR (MeOD, 400 MHz): δ 1.00(t, 3H), 1.52(m, 6H), 1.56-1.72(m, 8H), 1.98(m, 3H), 2.86(dd, 2H), 3.25(m, 1 H), 3.69(m, 1H), 4.42(m, 1 H); MS m/z = 264.

Example 11 (S)-3-((2-adamantyl)methyl)-5-phenyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 1 Steps 3 - 5 using (2-adamantylmethyl)amine in Step 3. ¹ H NMR (MeOD, 400 MH _Z ): δ 1.5(m, 2H),1.72(m,6H),1.82-2.00(m, 7H),3.38(m, 2H),3.51(m, 1 H),3.90(t, 1H),5.48(t, 1H),7.36-7.44(m, 5H); MS m/z = 312.

Example 12 (S)-3-(2-adamantyl)-5-tert-butyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 1 Steps 3 - 5 using (S)-2-hydroxy-3,3-dimethylbutanoic acid and 2- aminoadamantane hydrochloride in Step 3. ¹ H NMR (CDCI ₃ ) 0.94 (s, 9H), 1.60-2.0 ( 12H), 2.26 (br s, 1 H), 2.42 (br s, 1 H) ₁ 3.43 (t, 1 H) ₁ 3.62 (t, 1H), 3.69 (br s, 1 H), 4.14 (t, 1H); LC-MS (3 min) t _R = 2.09 min, m/z = 278.

Example 13 (S)-3-(1-hydroxy-4-adamantyl)-5-isobutyloxazolidiπ-2-one

The title compound was prepared following procedures analogous to those described in Example 1 Steps 3 - 5 using (S)-2-hydroxy-4-methylpentanoic acid and 1- hydroxy-4-aminoadamantane in Step 3. The isomers were separated by preparative HPLC to afford (S)-3-(1-hydroxy-4-adamantyl)-5-isobutyloxazolidin-2-one Isomer A and (S)-3-(1- hydroxy-4-adamantyl)-5-isobutyloxazolidin-2-one Isomer B. Isomer A: ¹ H NMR (MeOD, 400 MH _Z ): δ 0.98(d, 6H),1.52(m, 3H),1.76(m, 8H),1.86(m, 3H),2.14(m, 1H),2.46(m, 1 H),2.64(m, 1 H),3.56(m, 1 H),3.87(t, 1 H),4.60(m, 1 H).; MS m/z = 294. Isomer B: ¹ H NMR

(MeOD, 400 MH _Z ) δ 0 98(d, 6H), 1 48(m, 3H) 1 60(m, 2H), 1 74(m 7H), 1 88(m 3H),2 10(m, 1 H),2 56(m, 1 H),2 65(m, 1 H),3 47(m, 1 H),3 86(t, 1 H),4 60(m, 1 H), MS m/z = 294

Example 14 (S)-3-(2-adamantyl)-5-phenyloxazolιdιn-2-one

The title compound was prepared following procedures analogous to those described in Example 1 Steps 3 - 5 using (S)-2-hydroxy-2-phenylacetιc acid and 2- aminoadamantane hydrochloride in Step 3 ¹ H NMR (MeOD, 400 MH ₂ ) δ 1 55(m, 6H), 1 67(d, 2H), 1 75(m, 2H),1 91 (m, 8H),2 28(m, 1H),2 49(m, 1H),3 58(m, 1H),3 74(m, 1 H),4 09(m, 1 H),5 49(m, 1 H),7 40(m, 5H), MS m/z = 298

Example 15

(R)-3-(2-adamantyl)-5-phenyloxazolιdιn-2-one

The title compound was prepared following procedures analogous to those described in Example 1 Steps 3 - 5 using (R)-2-hydroxy-2-phenylacetιc acid and 2- aminoadamantane hydrochloride in Step 3 ¹ H NMR (MeOD, 400 MH _Z ) δ 1 56(m, 3H),1 66(d, 2H),1 86(m, 8H),2 28(m, 1H),2 48(m, 1H),3 54(t, 1 H),3 75(m, 1 H),4 07(m, 1 H),548(t, 1 H),7400(m, 5H), MS m/z = 298

Example 16 (S)-3-(2-adamantyl)-5-methyl-5-phenyloxazolιdιn-2-one

The title compound was prepared following procedures analogous to those described in Example 1 Steps 3 - 5 using (S)-2-hydroxy-2-phenylpropanoιc acid and 2- ammoadamantane hydrochloride in Step 3 ¹ H NMR (CDCI ₃ ) 1 50-1 90 (15H), 2 26 (br s, 1 H), 2 43 (br s, 1 H), 3 72 (s, 1 H), 3 79 (m, 2H), 7 25-7 45 (5H), LC-MS (3 mm) t _R = 2 11 mm, m/z = 286

Example 17 3-(1-adamantylmethyl)-5-(4-hydroxyphenyl)oxazolιdιn-2-one

Step i

To a stirred mixture of 4-hydroxybenzaldehyde (28.2 g, 231 mmol), potassium carbonate (47.9 g, 35 mmol), potassium iodide and DMF(280 ml.) benzyl bromide was added slowly at O ⁰ C. The mixture was stirred at rt overnight. The mixture was diluted with EtOAc and water. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with 1N aq HCI and dried. The solution was concentrated to give 4-benzyloxybenzaldehyde (46.5 g, 95%). ¹ H NMR: (CDCI ₃ , 400 MHz) δ=5.15 (s, 2H), 7.06 (m, 2H), 7.42(m, 5H), 7.84(m, 2H), 9.89(s, 1H).

Step 2

NaH (60%, 0.5 g, 23.6 mmol) was diluted in DMSO (50 ml.) and stirred for 30 min at rt under nitrogen. Trimethylsulfoxonium iodide (7.8 g, 35.37 mmol) was added in portions at 0 ⁰ C. The reaction mixture was stirred for 1 h. Then a solution of 4-benzyloxybenzaldehyde

(5 g, 23.58 mmol) in THF (15 mL) was added. The reaction solution was stirred at rt for 3 h.

The reaction mixture was poured into ice-water and extracted with ether. The organic layer was dried over Na ₂ SO ₄ and concentrated to give 2-(4-(benzyloxy)phenyl)oxirane, which was used for the next step without further purification.

Step 3

2-(4-(benzyloxy)phenyl)oxirane (2 g, 8.8 mmol) and (i-adamantylmethyl)amine (1.46 g, 8.8 mol) were dissolved in isopropyl alcohol (30 mL) and heated under reflux overnight.

The mixture was concentrated to give the crude product, which was purified by column chromatography to afford 1-(4-(benzyloxy)phenyl)-2-((1-adamantylmethyl)amino)ethanol

(0.8 g, 23%). ¹ H NMR: (CDCI ₃ , 400MH _z ) δ=1.51 (m, 6H), 1.60-1.72 (m, 6H), 1.97 (m, 3H),

2.32&2.45 (dd, 2H), 2.64 (m, 1H), 2.73 (m, 1 H), 2.94 (m, 1 H), 3.40 (brs, 3H), 4.79 (m, 1 H),

6.93 (m, 2H) ₁ 7.26-7.43 (m, 7H).

Step 4

To a solution of 1-(4-(benzyloxy)phenyl)-2-((1-adamantylmethyl)amino)ethanol (0.8 g, 2.05 mmol) in MeOH (10 ml) was added Pd(OH) ₂ (80 mg). The mixture was stirred at rt under H ₂ for 30 min. The mixture was filtered and concentrated to give 4-(2-((1- adamantylmethyl)amino)-1-hydroxyethyl)phenol (0.5 g, yield:81 %). ¹ H NMR: (CDCI ₃ ,

400MHz) δ=1.53 (m, 6H), 1.65 (m, 6H) ₁ 1.97 (m, 3H), 2.26 & 2.36 (dd, 2H), 2.62&2.83 (dd, 2H), 4.60 (m, 1 H), 6.78 (m, 2H), 7.22 (m, 2H).

Step 5 4-(2-((1-adamantylmethyl)amino)-1-hydroxyethyl)phenol (50 mg, 0.166 mmol) and

Et ₃ N (34 mg, 0.33 mmol) were dissolved in dry CH ₂ CI ₂ (1 ml_) and the solution was cooled to 0 ⁰ C. Triphosgene (19.7 mg, 0.066 mmol) in dry CH ₂ CI ₂ (1 mL) was added dropwise slowly. The mixture was allowed to warm to rt and stirred overnight. The solution was concentrated to give a residue, which was purified by preparative HPLC to afford 3- adamantan-1-ylmethyl-5-(4-hydroxy-phenyl)-oxazolidin-2-one (2.40 mg, 4.4%). ¹ H NMR: (CDCI ₃ , 400MHz): δ=1.54 (s, 6H), 1.58-1.65 (d, 3H), 1.66-1.75 (d, 3H), 1.99 (s, 3H), 2.80- 2.87 (d, 1H), 3.02-3.08 (d, 1H), 3.50-3.56 (t, 1 H), 3.93-4.00 (t, 1 H), 5.40-5.48 (t, 1H), 6.82- 6.90 (d, 1H), 7.20-7.26 (d, 1H); MS m/z = 328

Example 18

(S)-3-((1-adamantyl)methyl)-5-cyclohexyloxazolidin-2-one

t trn ⁱ pphnoos ^β gge ^β nne ^β

Step 1

To a solution of (S)-2-((1-adamantylmethyl)amino)-1-phenylethanol (50 mg, 0.18 mmol) in dry CH ₃ OH (5 mL) was added PtO ₂ (10 mg) as the catalyst The mixture was stirred under hydrogen (55 psi) at 60-70 ⁰ C overnight. After filtration, the filtrate was evaporated to give a residue, which was purified by preparative TLC to give (S)-1- cyclohexyl-2-((1-adamantylmethyl)amino)ethanol (20 mg, 40%). ¹ H NMR (MeOD, 400 MH _Z ): δ=1.07-1.99 (m, 25H), 2.35-2.51 (q, 2H), 2.63 (t, 1 H), 2.80 (d, 1 H), 3.51 (m, 1 H).

Step 2

To a solution of (S)-1-cyclohexyl-2-((1-adamantylmethyl)amiÏ€o)ethanol (22 mg, 0.077 mmol) and Et ₃ N (15.6 mg, 0.154 mmol) in dry CH ₂ CI ₂ (2 ml_) at 0 ⁰ C was added triphosgene (9.2 mg, 0.031 mmol) in dry CH ₂ CI ₂ (2 ml_). The mixture was stirred for 30 min and then concentrated in vacuum to give the crude product, which was purified by preparative TLC to afford (S)-3-((1-adamantyl)methyl)-5-cyclohexyloxazolidin-2-one (5 mg, 21 %). ¹ H NMR (MeOD, 400 MH _Z ): δ=1.18-1.97 (m, 25H), 2.75-2.95 (m, 2H), 3.42 (t, 1H), 3.72 (t, 1H), 4.83 (m, 1 H); MS: m/z = 318.

Example 19

(S)-3-((2-adamantyl)rnethyl)-5-cyclohexyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 18 using (S)-2-((2-adamantylmethyl)amino)-1-phenylethanol in Step 1. ¹ H NMR (MeOD, 400 MHz): δ 1.04(m, 2H),1.22(m, 3H),1.56(m, 8H),1.72(m, 7H),1.80- 2.00(m, 6H),3.25(m, 2H),3.47(m, 2H),4.20(m, 1H).; MS m/z = 318.

Example 20

(S)-3-(2-adamantyl)-5-cyclohexyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 18 using (S)-2-(2-adamantylamino)-1-phenylethanol in Step 1. ¹ H NMR (MeOD, 400 MH _Z ): δ 0.96-1.18 (m, 3H),1.19-1.36 (m, 3H),1.48-1.62 (m, 9H),1.76 (m, 4H),1.77-1.99 (m, 9H),2.23(m, 1 H) ,2.44(m, 1H) ,3.38(t, 1 H) ,3.70(m, 2H) ,4.18(m, 1 H); MS m/z = 304.

Example 21 (R)-3-(2-adamantyl)-5-cyclohexyloxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 18 using (R)-2-(2-adamantylamino)-1-phenylethanol in Step 1. ¹ H NMR (MeOD, 400 MH _Z ): δ 0.97-1.16(m, 3H),1.18-1.36(m, 4H),1.49-1.72(m, 11 H),1.75(m, 5H), 1.77-2.01 (m, 9H),2.23(m, 1 H),2.44(m, 1H),3.39(t, 1 H),3.60(m, 2H),4.17(m, 1 H); MS m/z = 304.

Example 22

3-(1-adamantylmethyl)-5-(4-hydroxycyclohexyl)oxazolidin-2 -one

Step i

To a solution of 4-(2-((1-adamantylmethyl)amino)-1-hydroxyethyl)phenol (0.3 g, 1 mmol) in MeOH (10 ml.) was added PtO ₂ (60 mg). The mixture was stirred under hydrogen (50 psi) at 60 ⁰ C for 2 d. The solvent was removed and purified by preparative TLC to give 4-(2-(1-adamantylmethylamino)-1-hydroxyethyl)cyclohexanol (100 mg, 32%). ¹ H NMR: (400 MH ₂ , CDCI ₃ ) δ=0.90-1.40 (m, 5H), 1.46 (m, 6H), 1.50-1.65 (m, 6H), 1.66-1.82 (m, 2H), 1.92 (m, 3H), 2.25 (m, 2H), 3.30 (m, 5H), 4.41 (m, 1H).

Step 2

To a solution of 4-(2-(1-adamantylmethylamino)-1-hydroxyethyl)cyclohexanol (180 mg, 0.58 mmol) and triethylamine (117 mg, 1.16 mmol) in CH ₂ CI ₂ (2 ml_), was added triphosgene (70 mg, 0.23 mmol). The mixture was stirred at rt overnight. The solvent was removed and the residue was purified by preparative TLC to give crude 3-(2-adamantyl)-5- (4-hydroxycyclohexyl)oxazolidin-2-one, which was separated by MS- trigger HPLC to afford isomer A (9.57 mg) and isomer B (2.27 mg).

Isomer A ¹ H NMR: (400 MH _Z , CDCI ₃ ) 5=1.14-1.31 (m, 4H), 1.56 (m, 11H), 1.63&1.73 (m, 4H), 2.05 (m, 4H), 2.74&2.99 (dd, 2H), 3.32 (m, 1 H), 3.62 (m, 2H), 4.23 (m, 1H); MS m/z = 334.

Isomer B ¹ H NMR: (400 M H _z , CDCI3) 6=1.31-1.50 (m, 3H), 1.50 (m, 6H), 1.62&1.71 (m, 6H), 1.82 (m, 2H), 2.00 (m, 3H), 2.16 (m, 6H), 2.72&3.03 (dd, 2H), 3.35 (m, 1 H), 3.64 (m, 1 H), 4.08 (m, 1H), 4.30 (m, 1 H); MS m/z = 334.

Example 23 3-((1-adamantyl)methyl)-6-isobutyl-1 ,3-oxazinan-2-one

LiAlH ₄ WPh∞gene

Step i

To a solution of 2,2-dimethyl-1 ,3-dioxane-4,6-dione (14.4 g, 0.1 mol) and pyridine (19.4 mL) in CH ₂ CI ₂ (150 mL) at 0 ° C, a solution of 3-methylbutyryl chloride (12 g, 0.1 mmol) in CH ₂ CI ₂ (140 mL) was added slowly. The reaction mixture was stirred for 1 h at 0 ⁰ C and for a further 1 h at rt. The mixture was concentrated to give a residue, which was diluted with EtOAc (500 mL) and filtered. The filtrate was washed with 10% aq Na ₂ CO ₃ (200 mL) and water (200 mL). The combined aqueous layers were extracted with EtOAc (100 mL). The combined organic layers were washed with brine (100 mL), dried over MgSO ₄ and concentrated to give crude 5-(3-methylbutanoyl)- 2,2-dimethyl-1 ,3- dioxane-4,6-dione (26 g), which was used in the next step without further purification.

Step 2

A solution of 5-(3-methylbutanoyl)-2,2-dimethyl-1 ,3-dioxane-4,6-dione (2.76 g, 12 mmol) and (i-adamantylmethyl)amine (2 g, 12 mmol) in anhydrous 1,4-dioxane (10 mL) was heated under reflux for 2 h. Solvent was removed in vacuo. The residue was diluted with EtOAc (50 mL), washed with water, aq K ₂ CO ₃ and brine, dried over Na ₂ SO ₄ and concentrated to dryness. The residue was purified by chromatography on a silica gel column eluted with 20:1 PE/EtOAc to give the N-(1-adamantylmethyl)-5-methyl-3- oxohexanamide (1.90 g, 54.4%). ¹ H NMR: (400MHz, CDCI ₃ ): δ=0.92 (s, 3H), 0.96 (s, 3H), 1.54 (s, 7H), 1.62-1.73 (m, 9H), 1.98 (s, 4H), 2.12(m, 1 H), 2.45(d, 2H), 2.95(d, 2H), 3.65(s, 2H).

Step 3 A solution of N-(1-adamantylmethyl)-5-methyl-3-oxohexanamide (1.5 g, 5.1 mmol) in anhydrous THF (15 mL) was added slowly to a suspension of LAH (500 mg, 13.1 mmol) in anhydrous THF (5 mL) under N ₂ at 0 ⁰ C. The reaction mixture was heated to 70 ⁰ C and stirred at this temperature overnight. Water (0.5 mL) and 10% aq NaOH (0.5 mL) were added to quench the reaction. The resulting slurry was filtered. The filtrate was concentrated in vacuo and the residue was purified by chromatography on a silica gel

column eluted with 10:1 PE/EtOAc to give 1-(1-adamantylmethylamino)-5-methylhexan-3-ol (900 mg, 63.3%). MS (M+1): 280.

Step 4

A solution of triphosgene (35 mg, 0.12 mmol) in anhydrous CH ₂ CI ₂ (500 μl_) was added slowly to a solution of 1-(1-adamantylmethylamino)-5-methylhexan-3-ol (100 mg, 0.36 mmol) and Et ₃ N (50 μl_, 0.257 mmol) in anhydrous CH ₂ CI ₂ (2 mL) at 0 ⁰ C. The reaction mixture was stirred for 1 h. Solvent was removed and the residue was purified by preparative TLC to give 3-((1-adamantyl)methyl)-6-isobutyl-1 ,3-oxazinan-2-one (80 mg, 74%). ¹ H NMR (MeOD, 400 MH _Z ): δ= 0.93-0.98 (q, 6H), 1.35-1.44 (m, 1 H), 1.50-2.08 (m, 18H), 2.87-2.94 (d, 1 H), 3.12-3.20 (d, 1 H), 3.30-3.40 (m, 1H), 3.49-3.61 (m, 1 H), 4.35-4.45 (m, 1 H); MS m/z = 306.

Example 24 (S)-1-((1-adamantyl)methyl)-4-(hydroxymethyl)imidazolidin-2- one

Step i

To a solution of (i-adamantylmethyl)amine (15 g, 52 mmol) in anhydrous CH ₂ CI ₂ (50 mL) was added tert-butyl 2-((tert-butyldimethylsilyloxy)methyl)aziridine-1-carboxylat e (13 g, 78.3 mmol). The mixture was stirred for 10 min, the solvent was removed in vacuo and the residue was stirred at 40 ⁰ C for 5 h. The mixture was diluted with EtOAc (500 mL) and washed with water (100 mL),1 N aq HCI (50 mL), satd aq NaHCO3 (50 ml) and brine (50 mL), and dried over MgSO ₄ . The solution was concentrated to give a residue, which was purified by chromatography on silica gel to give (S)-tert-butyl 1-(tert-butyldimethylsilyloxy)-3- ((1-adamantylmethyl)amino)propan-2-ylcarbamate (10 g, 24%). ¹ H NMR: (CDCI _3, 400MHz): δ=0.041 (S, 6H) ₁ 0.882 (s, 9H), 1.44 (s, 9H), 1.49 (s, 6H), 1.65 (m, 6H) ₁ 1.94 (S ₁ 3H), 2.23 (s, 2H), 2.62-2.81 (m, 2H), 3.67 (m, 3H), 5.30 (S ₁ 1 H).

Step 2

A solution of (S)-tert-butyl 1-(tert-butyldimethylsilyloxy)-3-((1- adamantylmethyl)amino)propan-2-ylcarbamate (10 g, 22 mmol) in 1N HCI in CH ₃ OH (30 ml.) was stirred for 3 h at it After the reaction was complete, the solution was concentrated to give crude (S)-2-amino-3-((1-adamantylmethyl)amino)propan-1-ol as its HCI salt, which was used for the next step without purification.

Step 3

To a solution of (S)-2-amino-3-((1-adamantylmethyl)amino)propan-1-ol HCI salt (1.2 g, 3.8 mmol) in anhydrous CH ₂ CI ₂ (20 mL) were added DIEA (1.9 g,15.2 mmol), DMAP (2.3 mg, 0.02 mmol) and TBDPSCI (1.2 g, 4.2 mmol) at 0 ⁰ C. The mixture was stirred at rt for 2 h. The reaction solution was extracted with CH ₂ CI ₂ (100 mL) and water (20 mL). The organic layer was washed with brine (20 mL), dried over MgSO ₄ , and concentrated to give the crude product, which was purified by preparative TLC (PE:EtOAc 10/1) to afford (S)-3- (tert-butyldiphenylsilyloxy)-N ¹ -(1-adamantylmethyl)propane-1,2-diamine (620 mg, 29%) ¹ H NMR: (CDCI ₃ ,400 MHz): δ=1.05 (s, 9H), 1.54 (s, 6H), 1.62-1.73 (m, 6H), 1.98 (s, 3H), 2.32 (d, 1 H), 2.45 (d, 1 H), 2.56 (d, 1H), 2.85 (d, 1 H), 3.15 (m, 4H) ₁ 3.65 (m, 2H), 7.4 (m, 6H), 7.62 (m, 4H).

Step 4

A solution of triphosgene (124 mg, 0.42 mmol) in anhydrous CH ₂ CI ₂ (2 mL) was added slowly to a solution of (S)-3-(tert-butyldiphenylsilyloxy)-N ¹ -(1- adamantylmethyl)propane-1 ,2-diamine (600 mg,1.26 mmol) and triethylamine ( 140 mg,1.4 mmol) in anhydrous CH ₂ CI ₂ (10 mL) at 0 ⁰ C. The reaction mixture was stirred for another 1 h. The mixture was diluted with water and extracted with CH ₂ CI ₂ (50 mL). The organic layer was washed with 0.1 N aq HCI (2 x 20 mL) and brine (10 mL), dried over MgSO ₄ and concentrated to give a residue, which was purified by preparative TLC to provide (S)-4-((tert- butyldiphenylsilyloxy)methyl)-1-(1-adamantylmethyl)imidazoli din-2-one (330 mg, 52%). ¹ H NMR: (CDCI ₃ , 400MHz): δ=1.05 (s, 9H), 1.54 (s, 6H), 1.62-1.73 (m, 8H), 1.98 (s, 3H), 2.77 (m, 2H), 3.21 (m, 1H), 3.55 (t, 1 H), 3.65 (m, 2H), 3.82 (m, 1 H), 4.57 (s, 1H), 7.4 (m, 6H), 7.62 (m, 4H).

Step 5

TBAF (400 mg, 1.6 mmol) was added to a solution of (S)-4-((tert- butyldiphenylsilyloxy)methyl)-1-(1-adamantylmethyl)imidazoli din-2-one (261 mg, 0.52 mmol) in anhydrous THF (5 mL) at 0 ⁰ C. The reaction was stirred at rt overnight. The reaction

solution was concentrated to give the residue, which was purified by preparative TLC (PE/EtOAc 1/1) to provide (S)-1-(1-adamantylmethyl)-4-(hydroxymethyl)imidazolidin-2-on e (45 mg, 10%). ¹ H NMR: (CDCI ₃ , 400 MHz): δ=1.54 (s, 6H), 1.62-1.73 (m, 6H), 1.98 (s, 3H), 2.77(m, 2H), 3.35 (m, 1 H), 3.55-3.75 (m, 3H), 3.82 (m, 1H); MS m/z = 265

Example 25 (4R,5S)-3-((1-adamantyl)methyl)-4-methyl-5-phenyloxazolidin- 2-one

Step i

To an ice-cold, stirred solution of (1S,2R)-2-amino-1-phenylpropan-1-ol (1.50 g, 9.9 mmol), DIEA (4.4 ml_, 24.8 mmol) in CH ₂ CI ₂ (50 ml_) was added solid adamantane-1- carbonyl chloride (4.34 g, 21.8 mmol). The mixture was stirred overnight, diluted with ether (150 ml_), washed with 5% aq HCI (50 ml_) and satd aq NaHCO ₃ (50 mL) and dried over MgSO ₄ . Removal over the solvent afforded a foam (4.78 g), which was dissolved in THF (50 mL) and MeOH (100 mL). 5% aq NaOH (50 mL) was added and the mixture was stirred at rt for 4 h. The mixture was rotovaped to remove the organic solvents and the aqueous residue was extracted with EtOAc (150 mL). The EtOAc extract was washed with brine (50 mL), dried over MgSO ₄ and concentrated to afford N-((1S,2R)-1-hydroxy-1-phenylpropan-2- yl)adamantane-1-carboxamide (3.07 g, 98%) as a sticky off-white solid. LC-MS (3 min) t _R = 1.78 min, m/z = 314, 296.

Step 2 A stirred solution of N-((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)adamantane-1- carboxamide (3.07 g, 9.8 mmol) in dry THF (50 mL) was cooled in an ice bath and 1M BH ₃ in THF (50 mL, 50 mmol) was added. The ice bath was allowed to melt and the mixture was stirred over the weekend at rt. The mixture was poured into 5% aq HCI (50 mL). The mixture was concentrated on the rotary evaporator to leave a white solid which was taken up in 5% aq HCI (75 mL) and washed with ether (150 mL). The aqueous layer was made

strongly basic by addition of NaOH and extracted with EtOAc (2 x 100 mL). The combined EtOAc extracts were dried over MgSO ₄ and concentrated to afford (1S,2R)-2-(1- adamantylmethylamino)-1-phenylpropan-1-ol (2.28 g, 77%) as an oil. LC-MS (3 min) t _R = 1.32 min, m/z = 300.

Step 3

To an ice-cold, stirred solution of (1S,2R)-2-(1-adamantylmethylamino)-1- phenylpropan-1-ol (715 mg, 2.4 mmol) and DIEA (1.3 mL, 7.2 mmol) in CH ₂ CI ₂ (50 mL) was added solid triphosgene (233 mg, 0.79 mmol). The ice bath was allowed to melt and the mixture was stirred at rt for 3 h. The mixture was diluted with ether (150 mL), washed with 5% aq HCI (50 mL) and satd aq NaHCO ₃ (50 mL), and dried over MgSO ₄ . Removal of the solvent left (4R,5S)-3-((1-adamantyl)methyl)-4-methyl-5-phenyloxazolidin- 2-one as a white solid. ¹ H NMR (CDCI ₃ ) 0.76 (d, 3H), 1.5-1.8 (12H), 2.01 (3H), 2.52 (d, 1H), 3.30 (d, 1H), 4.09 (m, 1 H), 5.63 (d, 1H), 7.25-7.40 (5H); LC-MS (3 min) t _R = 2.26 min, m/z = 326, 348.

Example 26

3-((1-adamantyl)methyl)-6-methyl-1 ,3-oxazinan-2-one

LiAIH ₄

triphosgene

Step 1

Adamantane-1-carboxylic acid (404 mg, 2.24 mmol), 4-amino-butan-2-ol (200 mg, 2.24 mmol), EDCI (885 mg, 4.48 mmol) and HOBt (605 mg, 4.48 mmol) were dissolved in anhydrous CH ₂ CI ₂ . DIEA (1.444 g, 11.2 mmol) was added to the above mixture at 0 ⁰ C under nitrogen. The mixture was stirred overnight and concentrated to give a residue, which was purified by preparative TLC to provide N-(3-hydroxybutyl)adamantane-1-carboxamide (170 mg, 30%). ¹ H NMR (MeOD, 400MHz): δ=1.20 (d, 3H), 1.66-2.04 (m, 17H), 2.87 (m, 2H), 3.79(m, 1 H).

Step 2

To a suspension of LiAIH ₄ (51 mg, 1 36 mmol) in THF (1 5 mL) was added a solution of N-(3-hydroxybutyl)adamantane-1 -carboxamide (170 mg, 0 68 mmol) in THF at 0 ⁰ C The mixture was stirred and heated under reflux overnight The reaction was quenched with H ₂ O (2 mL) The mixture was filtered to give 4-(1-adamantylmethylamιno)butan-2-ol (50 mg, 31%) ¹ H NMR (CD ₃ OD, 400 MH _Z ) δ=1 12 (d, 3H), 1 58-1 88 (m, 17H) 2 28 (t, 2H), 2 65 (m, 2H), 3 79 (m, 1 H)

Step 3 To a solution of 4-(1-adamantylmethylamιno)butan-2-ol (50 mg, 0 21 mmol) and Et ₃ N

(42 4 mg, 0 42 mmol) in CH ₂ CI ₂ (5 mL) at 0 °C under N ₂ , a solution of tÏ€phosgene (25 mg,

0 084 mmol) in CH ₂ CI ₂ (1 mL) was added dropwise The mixture was stirred at rt for 1 h The mixture was concentrated to give crude product, which was purified by preparative TLC to afford 3-((1-adamantyl)methyl)-6-methyl-1 ,3-oxazιnan-2-one (12 mg, 21 %) ¹ H NMR (CD ₃ OD, 400 MHz) δ=1 46 (d, 3H), 1 72-2 18 (m, 17H), 3 02 (d, 1H), 3 34 (d, 1H), 344 (m,

1 H), 3 63 (m, 1 H), 4 58 (m, 1 H), MS m/z =264

Example 27 (S)-1-(2-adamantyl)-4-tert-butylιmιdazolιdιn-2-one

R = H (major) R = H (major) R = Me (minor) R = Me (minor)

Step i

To a stirred slurry of Boc-t-Leu-OH (1 59 g, 6 8 mmol), 2-amιnoadamantane hydrochloride (1 28 g, 6 8 mmol) and DIEA (3 0 mL, 17 0 mmol) in CH ₂ CI ₂ (30 mL) was added solid HATU (2 86 g, 7 5 mmol) The mixture was stirred overnight at rt, diluted with ether (150 mL), washed with 5% aq HCI (50 mL) and satd aq NaHCO ₃ (50 mL) and dried

over MgSO ₄ . Removal of the solvent left crude (S)-tert-butyl 1-(2-adamantylamino)-3,3- dimethyl-1-oxobutaÏ€-2-ylcarbamate (2.08 g, 83%) as a tan solid. LC-MS (3 min) t _R = 2.17 min, m/z = 365.

Step 2

A stirred solution of crude (S)-tert-butyl 1-(2-adamantylamino)-3,3-dimethyl-1- oxobutan-2-ylcarbamate (2.08 g, 5.7 mmol) in dry THF (20 mL) was cooled in an ice bath and 1 M BH ₃ in THF (40 mL, 40 mmol) was added. The mixture was stirred at rt overnight and poured into 10% aq NaHCO ₃ (200 mL). the mixture was extracted with EtOAc (2 x 100 mL). The combined EtOAc extracts were washed with brine (100 mL), dried over MgSO ₄ and concentrated to afford a white solid (1.84 g). This material was dissolved in was dissolved in CH ₂ CI ₂ (30 mL) and TFA (5 mL) was added. After stirring for 1.5 h, satd aq NaHCO ₃ (100 mL) was added and the mixture was extracted with CH ₂ CI ₂ (3 x 50 mL). The combined CH ₂ CI ₂ extracts were dried over Na ₂ SO ₄ and concentrated to leave a white solid (1.92 g, ) which was used without purification in the next step. LC-MS showed the presence of (S)-N ¹ -(2-adamantyl)-3,3-dimethylbutane-1 ,2-diamine LC-MS(3 min) t _R = 0.74 min, m/z = 251 and (S)-N ¹ -(2-adamantyl)-N ² ,3,3-trimethylbutane-1 ,2-diamine LC-MS(3 min) t _R = 1.16 min, m/z = 265.

Step 3

A stirred solution of crude product from Step 2 (793 mg, 3.17 mmol) and DIEA (2 mL, 11.1 mmol) in CH ₂ CI ₂ (20 mL) was cooled in an ice bath and solid triphosgene (310 mg, 1.05 mmol) was added. The ice bath was allowed to melt. The mixture was stirred overnight at rt, diluted with ether (80 mL), washed with 5% aq HCI (2 x 20 mL) and satd aq NaHCO ₃ (20 mL) and dried over MgSO ₄ . Removal of the solvent left a syrup (0.80 g). Chromatography on a 40-g silica gel cartridge eluted with a 0-100% EtOAc in hexanes gradient afforded (S)-4-tert-butyl-1-(2-adamantyl)irnidazolidin-2-one (80 mg) as a white solid. ¹ H NMR (CDCI ₃ ) 0.90 (s, 9H), 1.5-2.0 (12H), 2.27 (s, 1 H), 2.39 (s, 1 H), 3.35 (m, 2H), 3.58 (t, 1H), 3.63 (s, 1 H), 4.42 (s, 1H); LC-MS (3 min) t _R = 2.01 min, m/z = 277. A mixed fraction (171 mg) containing crude (S)-1-(2-adamantyl)-4-tert-butyl-3-methylimidazolidin-2- one was also isolated.

Example 28 (S)-1-(2-adamantyl)-4-tert-butyl-3-methylimidazolidin-2-one

A portion of the mixed fraction from Example 27 Step 3 was purified by preparative HPLC to give (S)-1-(2-adamantyl)-4-tert-butyl-3-methylimidazolidin-2-one (1.2 mg). ¹ H NMR (CDCI ₃ ) 0.96 (s, 9H), 1.5-2.0 (12H), 2.36 (br s, 1 H), 2.39 (br s, 1H), 2.89 (s, 3H), 3.06 (dd, 1H), 3.21 (dd, 1 H), 3.42 (t, 1H), 3.58 (s, 1 H); LC-MS (3 min) t _R = 2.21 min, m/z = 291.

Example 29 (±)-5-(4-bromophenyl)-3-(2-adamantyl)oxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 17 Steps 3 and 5 using 4-bromostyrene and 2-aminoadamantane. ¹ H NMR (CDCI ₃ ) 1.6-2.0 (12H), 2.28 (s, 1 H), 2.44 (s, 1H), 3.52 (t, 1H), 3.75 (s, 1 H), 4.09 (t, 1 H), 5.41 (t, 1 H), 7.24 (d, 2H), 7.53 (d, 2H); LC-MS (3 min) t _R = 2.22 min, m/z = 376, 378.

Example 30 (S)-1-(1-adamantyl)-4-phenylimidazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 27 using (S)-Boc-Phg-OH. ¹ H NMR (MeOD, 400 MH _Z ): δ 1.6-2.2 (15H), 3.25 (m, 1H), 3.90 (m, 1H), 4.14 (m, 1 H), 7.2-7.4 (5H); MS m/z =297.

Example 31 (±)-4-tert-butyl-1 -(2-adamantyl)tetrahydropyrimidin-2(1 H)-one

The title compound was prepared following procedures analogous to those described in Example 27 using (±)-3-(tert-butoxycarbonylamino)-4,4-dimethylpentanoic acid. ¹ H NMR (CDCI ₃ ) 5.34(br s, 1 H), 4.09(s, 1 H), 3.64(m, 1H), 3.31 (td, 1 H), 3.07(m, 1 H), 2.19(s, 2H) ₁ 1.98-1.74(m, 10H) ₁ 1.72(8, 2H), 1.64(m, 4H), 0.97(s, 9H); LC-MS (3 min) t _R = 2.07 min, m/z = 291.

Example 32

(S)-4-cyclohexyl-1-(2-adamantyl)imidazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 27 using (S)-Boc-cyclohexylglycine. MS m/z = 303.

Example 33 (S)-4-isopropyl-1-(2-adamantyl)imidazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 27 using (S)-Boc-Val-OH. MS m/z = 263.

Example 34 (±)-5-(3-bromophenyl)-3-(2-adamantyl)oxazolidin-2-one

The title compound was prepared following procedures analogous to those described in in Example 17 Steps 3 and 5 using 3-bromostyrene and 2-aminoadamantane. 1.60-2.00 (12H), 2.27 (s, 1 H) ₁ 2.47 (s, 1H), 3.54 (t, 1H), 3.74 (s, 1 H) ₁ 4.09 (t, 1 H), 5.42 (t, 1H), 7.20-7.60 (4H). LC-MS (3 min) t _R = 2.20 min, m/z = 376, 378.

Example 35 (±)-1-(2-adamantyl)-4-(hydroxymethyl)-4-isobutylimidazolidi n-2-one

The title compound was prepared following procedures analogous to those described in Example 27 using (±)-2-(tert-butoxycarbonylarnino)-2-(hydroxymethyl)-4- methylpentanoic acid. MS m/z = 307.

Example 36 (±)-1-(1-adamantylmethyl)-4-(hydroxymethyl)-4-isobutylimida zolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 27 using (±)-2-(tert-butoxycarbonylamino)-2-(hydroxymethyl)-4- methylpentanoic acid and 1-(aminomethyl)adamantane. MS m/z = 321.

Example 37 (±)-5-(biphenyl-3-yl)-3-(2-adamantyl)oxazolidin-2-one

A mixture of (±)-5-(3-bromophenyl)-3-(2-adamantyl)oxazolidiÏ€-2-one (65 mg, 0.17 mmol), PhB(OH) ₂ (32 mg, 0.26 mmol) and n-PrOH (2 mL) was stirred at rt under an N ₂ atmosphere for 0.5 h. Solid Pd(OAaC) ₂ (2 mg, 0.009 mmol) and PPh ₃ (7 mg, 0.027 mmol) were added followed by a solution of Na ₂ CO ₃ (28 mg, 0.26 mmol) in water (1 mL). The mixture was heated at reflux for 1 h. The mixture was cooled, diluted with ether (150 mL), washed with 1M aq NaOH (50 mL), dried over MgSO ₄ and concentrtaed to leave a brown residue (69 mg). The residue was applied to a 2-g silica cartridge and eluted sequentially with 0, 10, 25, 50, 75 and 100% EtOAc in hexanes (15 mL of each) to give 6 fractions. Fraction 3 was concentrated to afford the title compound as an oil. ¹ H NMR (CDCI ₃ ) δ 1.60- 2.00 (12H), 2.26 (s, 1 H), 2.48 (s, 1 H), 3.61 (t, 1 H), 3.75 (s, 1H), 4.12 (t, 1H), 5.52 (t, 1H), 7.30-7.65 (9H). LC-MS (3 min) t _R = 2.24 min, m/z = 374.

Example 38 (±)-5-(biphenyl-4-yl)-3-(2-adamantyl)oxazolidin-2-one

The title compound was prepared following procedures analogous to those described in Example 37 using (+)-5-(4-bromophenyl)-3-(2-adamantyl)oxazolidin-2-one. ¹ H NMR (CDCI ₃ ) δ 1.60-2.00 (12H), 2.28 (s, 1H), 2.48 (s, 1 H), 3.60 (t, 1 H), 3.77 (s, 1H), 4.13 (t, 1 H), 5.49 (t, 1 H), 7.30-7.65 (9H). LC-MS (3 min) t _R = 2.30 min, m/z = 374.

PROPHETIC EXAMPLES The following Tables 1-7 provide additional examples of those compounds of the invention that could be prepared by the methods described herein.

Table 1

Example

R ¹ -(X) _n R^ Cy No.

1-

PE1 bond i-Pr H bond adamantyl

1-

PE2 bond cyclohexyl H bond adamantyl

1-

PE3 bond i-Bu CH ₂ OH bond adamantyl

1-

PE4 bond t-Bu Me bond adamantyl

2-

PE5 bond i-Pr H bond adamantyl

2-

PE6 bond cyclohexyl H bond adamantyl

2-

PE7 bond i-Bu CH ₂ OH bond adamantyl

2-

PE8 bond t-Bu Me bond adamantyl

1-

PE9 bond i-Pr H bond adamantyl

1-

PE10 bond cyclohexyl H CH ₂ adamantyl

1-

PE11 bond i-Bu CH ₂ OH CH ₂ adamantyl

1-

PE12 bond t-Bu Me CH ₂ adamantyl

PE13 bond 3-biphenyl Me bond 2-

adamantyl

2-

PE14 bond 4-biphenyl Me bond adamantyl

2-

PE15 bond 3-(3-pyridyl)phenyl Me bond adamantyl

2-

PE16 bond 3-(1-oxo-4-pyridyl)phenyl Me bond adamantyl

2-

PE17 bond 3-(2-carboxyphenyl)phenyl Me bond adamantyl

2-

PE18 bond 3-(3-carboxyphenyl)phenyl Me bond adamantyl

3-(2- 2-

PE19 bond Me bond methylsulfonylphenyl)phenyl adamantyl

3-(3- 2-

PE20 bond Me bond methylsulfonylphenyl)phenyl adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1- bond 2-FPh CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O CH ₂ adamantyl

Table 2

Example

R ¹ -(X) _rt Cy No

1-

PE21 bond ι-Pr Me bond adamantyl

1-

PE22 bond cyclohexyl Me bond adamantyl

1-

PE23 bond t-Bu Me bond adamantyl

2-

PE24 bond ι-Pr Me bond adamantyl

2-

PE25 bond cyclohexyl Me bond adamantyl

2-

PE26 bond t-Bu Me bond adamantyl

1-

PE27 bond i-Pr Me bond adamantyl

1-

PE28 bond cyclohexyl Me CH ₂ adamantyl

1-

PE29 bond t-Bu Me CH ₂ adamantyl

2-

PE30 bond 3-bιphenyl Me bond adamantyl

PE31 bond 4-bιphenyl Me bond 2-

adamantyl

2-

PE32 bond 3-(1-oxo-3-pyridyl)phenyl Me bond adamantyl

2-

PE33 bond 3-(4-pyridyl)phenyl Me bond adamantyl

2-

PE34 bond 3-(2-carboxyphenyl)phenyl Me bond adamantyl

2-

PE35 bond 3-(3-carboxyphenyl)phenyl Me bond adamantyl

3-(2- 2-

PE36 bond Me bond methylsulfonylphenyl)phenyl adamantyl

3-(3- 2-

PE37 bond Me bond methylsulfonylphenyl)phenyl adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O CH ₂ adamantyl

2- bond 4-(4-F-Ph)-Ph CH ₂ CH ₂ OH bond adamantyl

2- bond 4-(2-Me-4-pyridyl)-Ph CH ₂ CH ₂ CH ₂ OH bond adamantyl

2- bond 4-(1 -Me-6-oxo-3-pyridyl)-pH CH ₂ CMe ₂ OH bond adamantyl

2- bond 4-(4-F-Ph)-Ph CH ₂ CH ₂ CONH ₂ bond adamantyl

2- bond 4-(2-Me-4-pyridyl)-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me bond adamantyl

2- bond 4-(1-Me-6-oxo-3-pyridyl)-pH CH ₂ CH ₂ CONH ₂ bond adamaÏ€tyl

2- bond 4-(4-F-Ph)-Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O bond adamantyl

Table 3

Example

E R ¹ -(X)m R ² A Cy No.

1-

PE41 bond i-Pr H bond adamantyl

1 -

PE42 bond cyclohexyl H bond adamaπtyl

1-

PE43 bond i-Bu CH ₂ OH bond adamantyl

1 -

PE44 bond t-Bu Me bond adamantyl

2-

PE45 bond i-Pr H bond adamantyl

2-

PE46 bond cyclohexyl H bond adamantyl

2-

PE47 bond i-Bu CH ₂ OH bond adamantyl

2-

PE48 bond t-Bu Me bond adamantyl

PE49 bond i-Pr H bond 1 -

adamantyl

1-

PE50 bond cyclohexyl H CH ₂ adamantyl

1-

PE51 bond i-Bu CH ₂ OH CH ₂ adamantyl

1-

PE52 bond t-Bu Me CH ₂ adamantyl

2-

PE53 bond 3-biphenyl Me bond adamantyl

2-

PE54 bond 4-biphenyl Me bond adamantyl

2-

PE55 bond 3-(3-pyridyl)phenyl Me bond adamantyl

3-( 1-0X0-4- 2-

PE56 bond Me bond pyridyl)phenyl adamantyl

3-(2- 2-

PE57 bond Me bond carboxyphenyl)phenyl adamantyl

3-(3- 2-

PE58 bond Me bond carboxyphenyl)phenyl adamantyl

3-(2-methylsulfonyl 2-

PE59 bond Me bond phenyl)phenyl adamantyl

3-(3-methylsulfonyl 2-

PE60 bond Me bond phenyl)phenyl adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CHz) ₂ O CH ₂ adamantyl

.1- bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O CH ₂ adamantyl

Table 4

Example

R ¹ -(X), R^ Cy No.

1-

PE61 bond i-Pr H bond adamantyl

1-

PE62 bond cyclohexyl H bond adamantyl

1-

PE63 bond i-Bu CH ₂ OH bond adamantyl

1-

PE64 bond t-Bu Me bond adamantyl

2-

PE65 bond i-Pr H bond adamantyl

2-

PE66 bond cyclohexyl H bond adamantyl

2-

PE67 bond i-Bu CH ₂ OH bond adamantyl

2-

PE68 bond t-Bu Me bond adamantyl

1 -

PE69 bond ι-Pr H bond adamantyl

1-

PE70 bond cyclohexyl H CH ₂ adamantyl

1-

PE71 bond i-Bu CH ₂ OH CH ₂ adamantyl

1-

PE72 bond t-Bu Me CH ₂ adamantyl

2-

PE73 bond 3-bιphenyl Me bond adamantyl

2-

PE74 bond 4-bιphenyl Me bond adamantyl

3-( 1-0X0-3- 2-

PE75 bond Me bond pyrιdyl)phenyl adamantyl

2-

PE76 bond 3-(4-pyridyl)phenyl Me bond adamantyl

3-(2- 2-

PE77 bond Me bond carboxyphenyl)phenyl adamantyl

3-(3- 2-

PE78 bond Me bond carboxyphenyl)phenyl adamantyl

3-(2-methylsulfonyl 2-

PE79 bond Me bond phenyl)phenyl adamantyl

3-(3-methylsulfonyl 2-

PE80 bond Me bond phenyl)phenyl adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl bond 4-F-Ph ( 3H,CH,CH,NHSO,Me CH, 1-

adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O CH ₂ adamantyl

1 - bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1 - bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1 - bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1 - bond 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O CH ₂ adamantyl

Table 5

Example

R ¹ -(X)Ï€ Cy No.

1-

PE81 bond i-Pr Me bond adamantyl

1-

PE82 bond cyclohexyl Me bond adamantyl

1-

PE83 bond t-Bu Me bond adamantyl

2-

PE84 bond ι-Pr Me bond adamantyl

2-

PE85 bond cyclohexyl Me bond adamantyl

2-

PE86 bond t-Bu Me bond adamantyl

1-

PE87 bond ι-Pr Me bond adamantyl

1-

PE88 bond cyclohexyl Me CH ₂ adamantyl

1-

PE89 bond t-Bu Me CH ₂ adamantyl

2-

PE90 bond 3-bιphenyl Me bond adamantyl

2-

PE91 bond 4-bιphenyl Me bond adamantyl

2-

PE92 bond 3-(3-pyrιdyl)phenyl Me bond adamaπtyl

3-(1-oxo-4- 2-

PE93 bond Me bond pyrιdyl)phenyl adamantyl

3-(2- 2-

PE94 bond Me bond carboxyphenyl)phenyl adamantyl

3-(3- 2-

PE95 bond Me bond carboxyphenyl)phenyl adamantyl

3-(2-methylsulfonyl 2-

PE96 bond Me bond phenyl)phenyl adamantyl

3-(3-methylsulfonyl 2-

PE97 bond Me bond phenyl)phenyl adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl bond 4-F-Ph ( ^• ^H,CH,CH,NHSO,Me CH, 1-

adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CHz) ₂ O CH ₂ adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1 - bond 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O CH ₂ adamantyl

Table 6

Example

R ¹ -(X) _Ï€ Cy No.

~-

PE101 bond i-Pr H bond adamantyl

1-

PE102 bond cyclohexyl H bond adamantyl

1-

PE103 bond i-Bu CH ₂ OH bond adamantyl

1-

PE104 bond t-Bu Me bond adamantyl

2-

PE105 bond i-Pr H bond adamantyl

2-

PE106 bond cyclohexyl H bond adamantyl

2-

PE107 bond i-Bu CH ₂ OH bond adamantyl

2-

PE108 bond t-Bu Me bond adamantyl

1-

PE109 bond i-Pr H bond adamantyl

1-

PE110 bond cyclohexyl H CH ₂ adamantyl

1-

PE111 bond i-Bu CH ₂ OH CH ₂ adamantyl

1-

PE112 bond t-Bu Me CH ₂ adamantyl

2-

PE113 bond 3-biphenyl Me bond adamantyl

2-

PE114 bond 4-biphenyl Me bond adamantyl

3-( 1-0X0-3- 2-

PE115 bond Me bond pyridyl)phenyl adamantyl

2-

PE116 bond 3-(4-pyridyl)phenyl Me bond adamantyl

3-(2- 2-

PE117 bond Me bond carboxyphenyl)phenyl adamantyl

3-(3- 2-

PE118 bond Me bond carboxyphenyl)phenyl adamantyl

3-(2-methylsulfonyl 2-

PE119 bond Me bond phenyl)phenyl adamantyl

3-(3-methylsulfonyl 2-

PE120 bond Me bond phenyl)phenyl adamantyl bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ 1-

adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1 - bond 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O CH ₂ adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1- bond 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1 - bond Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1 - bond 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1- bond Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O CH ₂ adamantyl

Table 7

Example

Q E-R ¹ -(X) _m R ² A Cy No.

1-

PE121 NH i-Pr H bond adamantyl

1-

PE122 NH cyclohexyl H bond adamantyl

1-

PE123 NH i-Bu CH ₂ OH bond adamantyl

1-

PE124 NH t-Bu Me bond adamantyl

2-

PE125 NH i-Pr H bond adamantyl

2-

PE126 NH cyclohexyl H bond adamantyl

2-

PE127 NH i-Bu CH ₂ OH bond adamantyl

2-

PE128 NH t-Bu Me bond adamantyl

1-

PE129 NH i-Pr H bond adamantyl

1-

PE130 NH cyclohexyl H CH ₂ adamantyl

1-

PE131 NH i-Bu CH ₂ OH CH ₂ adamantyl

1-

PE132 NH t-Bu Me CH ₂ adamantyl

1-

PE133 NMe i-Pr H bond adamantyl

1-

PE134 NMe cyclohexyl H bond adamantyl

1-

PE135 NMe i-Bu CH ₂ OH bond adamantyl

1-

PE136 NMe t-Bu Me bond adamantyl

2-

PE137 NMe i-Pr H bond adamantyl

2-

PE138 NMe cyclohexyl H bond adamantyl

2-

PE139 NMe i-Bu CH ₂ OH bond adamaÏ€tyl

2-

PE140 NMe t-Bu Me bond adamantyl

1-

PE141 NMe i-Pr H bond adamantyl

1-

PE142 NMe cyclohexyl H CH ₂ adamantyl

1-

PE143 NMe i-Bu CH ₂ OH CH ₂ adamantyl

1-

PE144 NMe t-Bu Me CH ₂ adamantyl

1-

PE145 O i-Pr H bond adamantyl

1-

PE146 O cyclohexyl H bond adamantyl

1-

PE147 O t-Bu Me bond adamantyl

2-

PE148 O i-Pr H bond adamantyl

2-

PE149 O cyclohexyl H bond adamantyl

2-

PE150 O t-Bu Me bond adamantyl

1-

PE151 O i-Pr H bond adamantyl

1-

PE152 O cyclohexyl H CH ₂ adamantyl

1-

PE153 O t-Bu Me CH ₂ adamantyl

2-

PE154 O 3-bιphenyl Me bond adamantyl

2-

PE155 NH 4-bιphenyl Me bond adamantyl

2-

PE156 O 3-(3-pyridyl)phenyl Me bond adamantyl

3-(1 -oxo-4- 2-

PE157 NH Me bond pyridyl)phenyl adamantyl

PE158 O 3-(2- Me bond 2-

carboxyphenyl)phenyl adamantyl

3-(3- 2-

PE159 NH Me bond carboxyphenyl)phenyl adamantyl

3-(2-methylsulfonyl 2-

PE160 O Me bond phenyl)phenyl adamantyl

3-(3-methylsulfonyl 2-

PE161 NH Me bond phenyl)phenyl adamantyl

1-

O 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1-

NH 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1-

NMe Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1-

O Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1-

NH 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1-

NMe 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1 -

O Ph CH ₂ CH ₂ N(CH ₂ CHs) ₂ O CH ₂ adamantyl

1 -

NH 4-F-Ph CH ₂ CH ₂ OH CH ₂ adamantyl

1-

NMe 2-F-Ph CH ₂ CH ₂ CH ₂ OH CH ₂ adamantyl

1-

O Ph CH ₂ CMe ₂ OH CH ₂ adamantyl

1 -

NH Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1-

NMe 4-F-Ph CH ₂ CH ₂ CH ₂ NHSO ₂ Me CH ₂ adamantyl

1 -

O 2-F-Ph CH ₂ CH ₂ CONH ₂ CH ₂ adamantyl

1-

O Ph CH ₂ CH ₂ N(CH ₂ CH ₂ ) ₂ O CH ₂ adamantyl

The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present

invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneous^, subcutaneously, intraduodenally, or intraperitoneal^. Additionally, the compounds of the present invention can be administered intranasally or transdermally. -It will be obvious to those skilled in the art that the following dosage forms may comprise as the active ingredient, either compounds or a corresponding pharmaceutically acceptable salt of a compound of the present invention.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can either be solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active ingredient.

In tablets, the active ingredient is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from about one to about seventy percent of the active ingredient. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium caboxymethylcellulose, a low-melting wax, cocoa butter, and the like. Tablets, powders, cachets, lozenges, fast-melt strips, capsules and pills can be used as solid dosage forms containing the active ingredient suitable for oral administration.

For preparing suppositories, a low-melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first-melted and the active ingredient is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, retention enemas, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral administration can be prepared by dissolving the active ingredient in water and adding suitable colorants, flavors, stabilizing, and thickening

agents as desired. Aqueous suspensions for oral administration can be prepared by dispersing the finely divided active ingredient in water with viscous material, such as natural or synthetic gums , resins, methylcellulose, sodium carboxymethylcellulose, and other well- known suspending agents.

The pharmaceutical composition is preferably in unit dosage form. In such form, the composition is subdivided into unit doses containing appropriate quantities of the active ingredient. The unit dosage form can be a packaged preparation, the package containing discrete quantities of, for example, tablets, powders, and capsules in vials or ampules. Also, the unit dosage form can be a tablet, cachet, capsule, or lozenge itself, or it can be the appropriate amount of any of these in packaged form.

The quantity of active ingredient in a unit dose preparation may be varied or adjusted from about 0.1 mg to about 1000.0 mg, preferably from about 0.1 mg to about 100 mg. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill in the art. Also, the pharmaceutical composition may contain, if desired, other compatible therapeutic agents.

In therapeutic treatment or as a method-of-use as an inhibitor of 11 β-HSD1 or an inhibitor in the production of Cortisol in the cell, the active ingredient is preferably administered orally in a solid dosage form as disclosed above in an amount of about 0.1 mg to about 100 mg per daily dose where the dose is administered once or more than once daily.

BIOLOGICAL ASSAYS

The inhibition of purified 11β-HSD1 by compounds of Formula I was measured as follows using a Scintillation Proximity Assay. All reactions were carried out at room temperature in 96 well flexible Microbeta reaction plates. The assay begins by adding 1 microliter of a 0.1 mM solution of a compound of Formula I in DMSO previously diluted in half-log increments (8 points) starting at 1 micromolar final concentration. To this dot was added 50 microliters of substrate solution (5OmM HEPES ₁ pH 7.4, 10OmM KCI, 5mM NaCI, 2mM MgCI2 containing 20 microliters of ³ H cortisone, 1mM NADPH). After a 10 minute incubation, 50 microliters of enzyme solution containing 20 nM recombinant 11 β-HSD1 (expressed in E. coli, and affinity purified) was added, The reaction was incubated for 90

minutes, and stopped by adding 50 microliters of SPA bead mix (18-β-glycyrrhetιnιc acid, 10 micromolar final, 5 mg/ml protein A coated YSi SPA beads, and 1-mιcrogram/ml alpha- cortisol antibody (East Coast Biologies) The plate shaken for 120 minutes, and the radioactivity corresponding to ³ H Cortisol was measured on a Wallac Microbeta

The inhibition of microsomal 11β-HSD1 was carried out in the same manner

The inhibition of 11β-HSD1 by compounds of Formula I in whole cells was measured as follows Omental adipocytes cultured in 96-well plates were purchased from Zen-Bio, lnc and used at least two weeks after differentiation from precursor preadipocytes started in medium supplemented with adipogenic and lipogenic hormones (human insulin, dexamethasone, isobutylmethylxanthine and PPAR-gamma agonist) The cells were maintained in full adipocyte medium (DMEM/Ham's F-12 (1 1, v/v), HEPES pH 7 4, fetal bovine serum, penicillin, streptomycin and Amphotericin B, supplied by Zen-Bio, lnc ) at 37 degrees C, 5% CO2 and transferred into serum-free, phenol red free medium for overnight incubation The assay was performed in a total volume of 200 microliters The cells were pre-incubated with serum-free, phenol red free medium containing 0 1% (v/v) of DMSO and various concentrations of compounds of Fomula I at least 1 h before [ ³ H] cortisone in ethanol (50Cι/mmol, ARC, lnc ) was added to achieve final concentration of cortisone of 100 nM The cells were incubated for 3-4 at 37 degrees Centigrade, 5% CO2 Negative controls were incubated without radioactive substrate and received the same amount of [ ³ H] cortisone at the end of the incubation Formation of [ ³ H] Cortisol was monitored by analyzing 25 microliters of each supernatant in scintillation proximity assay (SPA) (Solly, K , Mundt, S S .Zokian, H J ,Dιng, G J , Hermanowski-Vosatka, A , Strulovici, B , Zheng, W Assay Drug Dev Technol 2005, 3, 377-384),

Table 8

Inhibition of Inhibition of Inhibition of

Example purified 11 β- microsomal 11 β-HSD1 in HSD1 ^a 11β-HSD1 ^a whole cells ^a

1 ++ nt +

2 ++ nt +

3 + nt nt

4 ++ nt ++

++ nt ++

+ nt nt

++ nt + ++ nt ++

+ nt nt

+ nt nt

+ nt nt

++ ++ ++ A nt nt B nt nt

+ nt nt

+ nt nt ++ nt ++

+ nt nt ++ nt +

+ nt nt

++ nt ++ 1 ++ nt ++ A + nt nt B + nt nt 3 + nt nt

+ nt nt 5 ++ nt ++ 6 + nt nt 7 ++ nt ++ 8 ++ ++ ++ 9 nt ++ nt

30 nt ++ +

31 nt ++ ++

32 nt ++ ++

33 nt ++ ++

34 nt ++ nt

35 nt ++ nt

36 nt + nt

37 nt ++ +

38 nt ++ nt

^a ++ means IC ₅₀ < 50 nM, + means IC ₅₀ = 50 nM to 1000 nM, - means IC ₅₀ > 1000 nM, nt means not tested.

The compounds of the invention are useful for ameliorating or treating disorders or diseases in which decreasing the level of Cortisol is effective in treating a disease state. Thus, the compounds of the invention can be used in the treatment or prevention of diabetes mellitus, obesity (especially abdominal obesity), symptoms of metabolic syndrome, prothrombotic state, proinflammatory state, glucose intolerance, hyperglycemica, hypertension, hyperlipidemia, insulin resistance, cardiovascular disease, dyslipidemia, atherosclerosis, lipodystrophy, osteoporosis, glaucoma, Cushing's syndrome, Addison's Disease, visceral fat obesity associated with glucocorticoid therapy, depression, anxiety, Alzheimer's disease, dementia, cognitive decline (including age-related cognitive decline), polycystic ovarian syndrome, infertility and hypergonadism. In addition, the compounds modulate the function of B and T cells of the immune system and can therefore be used to treat diseases such as tuberculosis, leprosy and psoriasis. They can also be used to promote wound healing, particularly in diabetic patients.

Additional diseases or disorders that are related to 11 (3-HSD1 activity include those selected from the group consisting of lipid disorders, hypretriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, vascular restenosis, pancreatitis, abdominal obesity, neurodegenerative disease, retinopathy, nephropathy, neuropathy, diabetes, coronary heart disease, stroke, peripheral vascular disease, Cushing's syndrome, hyperinsulinemia, viral diseases, and Syndrome X.

A pharmaceutical composition of the invention may, alternatively or in addition to a compound of Formula I, comprise a pharmaceutically acceptable salt of a compound of Formula I or a prodrug or pharmaceutically active metabolite of such a compound or salt and one or more pharmaceutically acceptable carriers therefore.

The compositions of the invention are 11β-HSD1 inhibitors. Said compositions contain compounds having a mean inhibition constant (IC5 ₀ ) against 11β-HSD1 of between about 1 ,000 nM to about 0.001 nM; preferably between about 50 nM to about 0.001 nM; and more preferably between about 5 nM to about 0.001 nM,

The invention includes a therapeutic method for treating or ameliorating an 11β- HSD1 mediated disorder in a subject in need thereof comprising administering to a subject in need thereof an effective amount of a compound of Formula I ₁ or the enantiomers, diastereomers, or salts thereof of composition thereof.

An embodiment of the invention includes administering an 11β-HSD1 inhibiting compound of Formula I or composition thereof alone or in a combination therapy with one or more additional agents for the treatment of diabetes, dyslipidemia, cardiovascular disease, hypertension, obesity, cancer or glaucoma. Agents for the treatment of diabetes include insulins, such as Humulin® (EIi Lilly), Lantus® (Sanofi Aventis), Novolin (Novo

Nordisk), and Exubera® (Pfizer); PPAR gamma agonists, such as Avandia® (rosiglitizone maleate, GSK) and Actos® (pioglitazone hydrochloride, Takeda/Eli Lilly); sulfonylureas, such as Amaryl® (glimepiride, Sanofi Aventis), Diabeta® (glyburide, Sanofi Aventis), Micronase®/Glynase® (glyburide, Pfizer), and Glucotrol®/Glucotrol XL® and (glipizide, Pfizer); meglitinides, such as Prandin®/NovoNorm® (repaglinide, Novo Nordisk), Starlix® (nateglinide, Novartis), and Glufast® (mitiglinide, Takeda); biguanides, such as Glucophase®/Glucophase XR® (metformin HCI, Bristol Myers Squibb) and Glumetza (metformin HCI, Depomed); thiazolidinediones; amylin analogs, GLP-1 analogs; DPP-IV inhibitors; PTB-1 B inhibitors; protein kinase inhibitors (including AMP-activated protein kinase inhibitors); glucagon antagonists, glycogen synthase kinase-3 beta inhibitors; glucose-6-phoshatase inhibitors; glycogen phosphorylase inhibitors; sodium glucose co- transporter inhibitors, and alpha-glucosidase inhibitors, such as

Precose®/Glucobay®/Prandase®/Glucor® (acarbose, Bayer) and Glyset® (miglitol, Pfizer). Agents for the treatment of dyslipidemia and cardiovascular disease include statins, fibrates, and ezetimbe. Agents for the treatment of hypertension include alpha-blockers, beta- blockers, calcium channel blockers, diuretics, angiotensin converting enzyme (ACE)

inhibitors, dual ACE and neutral endopeptidase (NEP) inhibitors, angiotensin-receptor blockers (ARBs), aldosterone synthase inhibitor, aldosterone-receptor antagonists, or endothelin receptor antagonist. Agents for the treatment of obesity include orlistat, phentermine, sibutramine and rimonabant.

An embodiment of the invention includes administering an 11β-HSD1 inhibiting compound of Formula I or composition thereof in a combination therapy with one or more other 11 β-HSD1 inhibitors (whether such inhibitors are also compounds of Formula I or are compounds of a different class/genus), or with combination products, such as Avandamet® (metformin HCI and rosiglitazone maleate, GSK); Avandaryl® (glimepiride and rosiglitazone maleate, GSK); Metaglip® (glipizide and metformin HCI, Bristol Myers Squibb); and Glucovance® (glyburide and metformin HCI, Bristol Myers Squibb).